Protocol Number: NERD -201 
Official Title: A Phase 2, Randomized, Double- Blind, Multicenter Study to Evaluate the Efficacy and 
Safety of Vonoprazan 10 mg, 20 mg, and 40 mg Compared to Placebo for Relief of Episodic 
Heartburn in Subjects with Symptomatic Non- Erosive Gastroesophageal R eflux Disease  
Document Date: 16 July 2021  
Study ID: [REMOVED] 
 
Phathom Pharmaceuticals, Inc. vonoprazan 
Protocol: NERD-201 Version 2.0, Amendment 1 16 July 2021 
Page 2 Protocol Approval ‚Äì Sponsor Signatory 
Study Title A Phase 2, Randomized, Double-Bli nd, Multicenter Study to Evaluate 
the Efficacy and Safety of V onoprazan 10 mg, 20 mg, and 40 mg 
Compared to Placebo for Relief of Episodic Heartburn in Subjects 
with Symptomatic Non-Erosive Gastroesophageal Reflux Disease  
Protocol Number NERD-201 
Protocol Version 
and Date Version 2.0, Amendment 1 
16 July 2021 
Protocol accepted and approved by:  
Vice President Clinical and Patient Safety  
 
 
 
 
      


			

Phathom Pharmaceuticals, Inc. vonoprazan 
Protocol: NERD-201 Version 2.0, Amendment 1 16 July 2021 
Page 3 Protocol Approval ‚Äì Sponsor Signatory 
Study Title A Phase 2, Randomized, Double-Bli nd, Multicenter Study to Evaluate 
the Efficacy and Safety of V onoprazan 10 mg, 20 mg, and 40 mg 
Compared to Placebo for Relief of  Episodic Heartburn in Subjects 
with Symptomatic Non-Erosive Gastroesophageal Reflux Disease  
Protocol Number NERD-201 
Protocol Version 
and Date Version 2.0, Amendment 1 
16 July 2021 
Protocol accepted and approved by:  
Chief Operating Officer  
 
 
 
 
     
 	

	

Phathom Pharmaceuticals, Inc. vonoprazan 
Protocol: NERD-201 Version 2.0, Amendment 1 16 July 2021 
Page 4 Protocol Approval ‚Äì Sponsor Signatory 
Study Title A Phase 2, Randomized, Double-Bli nd, Multicenter Study to Evaluate 
the Efficacy and Safety of V onoprazan 10 mg, 20 mg, and 40 mg 
Compared to Placebo for Relief of  Episodic Heartburn in Subjects 
with Symptomatic Non-Erosive Gastroesophageal Reflux Disease  
Protocol Number NERD-201 
Protocol Version 
and Date Version 2.0, Amendment 1 
16 July 2021 
Protocol accepted and approved by:  
Chief Medical Officer  
 
 
 
 
      	



		


	

Phathom Pharmaceuticals, Inc. vonoprazan 
Protocol: NERD-201 Version 2.0, Amendment 1 16 July 2021 
Page 5 Protocol Approval ‚Äì Lead Statistician 
Study Title A Phase 2, Randomized, Double-Bli nd, Multicenter Study to Evaluate 
the Efficacy and Safety of V onoprazan 10 mg, 20 mg, and 40 mg 
Compared to Placebo for Relief of  Episodic Heartburn in Subjects 
with Symptomatic Non-Erosive Gastroesophageal Reflux Disease 
Protocol Number NERD-201 
Protocol Version 
and Date Version 2.0, Amendment 1 
16 July2021 
Protocol accepted and approved by:Lead Statistician 
 
 
 
      


	

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 7 Declaration of Investigator  
I have read and understood all sections of the protocol entitled ‚ÄúA Phase 2, Randomized, 
Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg, 20 mg, and 40 mg Compared to Placebo for Relief of Episodic Heartburn in Subjects with Symptomatic Non -Erosive Gastroesophageal Reflux Disease‚Äù and the accompanying 
investigator‚Äôs brochure. 
I agree to supervise all aspects of the protocol and to conduct the clinical investigation in 
accordance with the Final Protocol Version 2.0, Amendment 1, dated 16 July 2021, the International Council for Harmonisation harmonised tripartite guideline E6 R2: Good 
Clinical Practice, and all applicable government regulations. I will not make changes to the 
protocol before consulting with Phathom Pharmaceuticals, Inc. or implement protocol changes without Institutional Review Boards/Independent Ethics Committees approval 
except to eliminate an immediate risk to subjects. I agree to administer study drug only to 
subjects under my personal supervision or the supervision of a subinvestigator. 
I will not supply the investigational drug to any person not authorized to receive it. 
Confidentiality will be protected. Subject identity will not be disclosed to third parties or 
appear in any study reports or publications. 
I will not disclose information regarding this clinical investigation or publish results of the 
investigation without authorization from Phathom Pharmaceuticals, Inc. 
 
 
   
Signature of Principal Investigator   Date  
 
 
   
Printed Name of Principal Investigator    
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 8 Table of Contents  
Table of Contents .......................................................................................................................8  
List of Tables  ............................................................................................................................12  
List of Figures ..........................................................................................................................13  
Protocol Synopsis.....................................................................................................................14  
List of Abbreviations ................................................................................................................20  
Summary of Changes ...............................................................................................................22  
1 Introduction ......................................................................................................................23  
1.1 Study Rationale .......................................................................................................23  
1.2 Background .............................................................................................................23  
1.3 Justification for Dose  ..............................................................................................25  
2 Study Objectives and Endpoints ......................................................................................27  
2.1 Primary Objectives and Endpoints..........................................................................27  
2.2 Secondary Objectives and Endpoints......................................................................27  
3 Investigational Plan  ..........................................................................................................30  
3.1 Study Design ...........................................................................................................30  
3.1.1  Rationale of Study Design .......................................................................33  
3.1.1.1  Rationale for the Run- In Period  ...............................................................33  
3.1.1.2  Rationale for the On -Demand Treatment Period  .....................................33  
4 Subject Selection and Withdrawal Criteria  ......................................................................34  
4.1 Selection of Study Population .................................................................................34  
4.1.1  Selection for Run- In Period  .....................................................................34  
4.1.1.1  Inclusion Criteria for Run -In Period  ........................................................34  
4.1.1.2  Exclusion Criteria for Run- In Period  .......................................................35  
4.1.1.3  Screen Failures  .........................................................................................38  
4.1.2  Selection for On -Demand Treatment Period  ...........................................38  
4.1.2.1  Inclusion Criteria for On -Demand Treatment Period  ..............................38  
4.1.2.2  Run- In Failures  ........................................................................................39  
4.1.3  Lifestyle Considerations ..........................................................................39  
4.2 Withdrawal of Subjects From Study Drug and/or the Study ..................................39  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 9 4.2.1  Reasons for Withdrawal/Discontinuati on ................................................39  
4.2.2  Handling of Withdrawals  .........................................................................41  
4.2.3  Lost to Follow-up.....................................................................................42  
4.2.4  Replacements  ...........................................................................................42  
5 Study Drugs ......................................................................................................................43  
5.1 Method of Assigning Subjects to Treatment Groups ..............................................43  
5.2 Treatments Administered  ........................................................................................43  
5.2.1  Run- In Period  ...........................................................................................43  
5.2.2  On-Demand Treatment Period  .................................................................43  
5.3 Rescue Antacid ........................................................................................................44  
5.4 Identity of Investigational Product and Rescue Antacid .........................................44  
5.4.1  V onoprazan and Placebo ..........................................................................44  
5.4.2  Rescue Antacid  ........................................................................................44  
5.5 Management of Clinical Supplies ...........................................................................45  
5.5.1  Study Drug Packaging and Storage .........................................................45  
5.5.2  Test Article and Rescue Antacid Accountability  ......................................45  
5.6 Overdose Management  ...........................................................................................45  
5.6.1  Treatment of Overdose ............................................................................46  
5.7 Blinding...................................................................................................................46  
5.7.1  Breaking the B lind ...................................................................................46  
5.8 Study Compliance ...................................................................................................47  
5.8.1  Treatment Compliance  .............................................................................47  
5.8.2  Diary Compliance ....................................................................................47  
5.9 Prior and Concomitant Therapy ..............................................................................47  
5.9.1  Background Medications .........................................................................48  
5.9.2  Excluded Medications..............................................................................49  
6 Study Assessments and Procedures ..................................................................................50  
6.1 Endoscopy ...............................................................................................................50  
6.2 Efficacy Assessments  ..............................................................................................50  
6.2.1  Electronic Diary  .......................................................................................50  
6.2.1.1  Morning and Evening Heartburn Diary ...................................................51  
6.2.1.2  Rescue Antacid Diary  ..............................................................................51  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 10 6.2.1.3  On-Demand Heartburn Episode Diary ....................................................51  
6.2.1.4  On-Demand Heartburn Timed Assessments  ............................................51  
6.2.1.5  Severity Definitions  .................................................................................51  
6.2.2  PAGI -SYM Questionnaire .......................................................................52  
6.2.3  PAGI -QoL Questionnaire ........................................................................53  
6.2.4  Patient Global Impression of Change Questionnaire ...............................53  
6.2.5  Patient Global Impression of Severity Questionnaire ..............................53  
6.2.6  Patient Preference Questionnaire  .............................................................53  
6.3 Safety Assessments  .................................................................................................54  
6.3.1  Pretreatment Events and Adverse Events  ................................................54  
6.3.1.1  Definitions  ...............................................................................................54  
6.3.1.2  Docume nting Adverse Events  ..................................................................60  
6.3.1.3  Time Period and Frequency for Collecting AE and SAE Information ....62  
6.3.1.4  Regulatory Reporting Requirements for SAEs ........................................65  
6.3.2  Pregnancy .................................................................................................66  
6.3.3  Laboratory A nalyses  ................................................................................67  
6.3.4  Physical Examinations .............................................................................69  
6.3.5  Vital Signs  ................................................................................................69  
6.3.6  Electrocardiograms  ..................................................................................70  
6.4 Safety Monitoring Committee  ................................................................................70  
7 Statistical and Analytical Plan  ..........................................................................................71  
7.1 Sample Size Calculations  ........................................................................................71  
7.2 Analysis Sets  ...........................................................................................................72  
7.2.1  All Subjec ts Set  ........................................................................................72  
7.2.2  Safety Sets ................................................................................................72  
7.2.3  Intent- to-Treat Set  ....................................................................................72  
7.3 Description of Subgroups .......................................................................................73  
7.4 Statistical Analysis Methodology  ...........................................................................73  
7.4.1  Efficacy Analyses  ....................................................................................74  
7.4.1.1  Primary Efficacy Endpoint ......................................................................74  
7.4.1.2  Secondary Efficacy Endpoint ..................................................................74  
7.4.1.3  Exploratory Endpoints On- Demand Treatment Period  ............................75  
7.4.1.4  Exploratory Endpoints Run- In Period  .....................................................76  
7.4.2  Safety Analyses  ........................................................................................77  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 11 7.4.3  Other Analyses  .........................................................................................78  
7.4.4  Interim Analyses  ......................................................................................78  
8 Data Quality Assurance  ....................................................................................................79  
8.1 Data Management  ...................................................................................................79  
9 Ethics  ................................................................................................................................80  
9.1 Independent Ethics Committee or Institutional Review Board ..............................80  
9.2 Ethical Conduct of the Study ..................................................................................80  
9.3 Subject Information and Consent............................................................................80  
10 Investigator‚Äôs Obligations ................................................................................................82  
10.1  Confidentiality  ........................................................................................................82  
10.2  Financial Disclosure and Obligations .....................................................................82  
10.3  Investigator Documentation ....................................................................................83  
10.4  Study Conduct .........................................................................................................83  
10.5  Adherence to Protocol.............................................................................................83  
10.6  Adverse Events and Study Report Requirements ...................................................84  
10.7  Investigator‚Äôs Final Report .....................................................................................84  
10.8  Records Retention  ...................................................................................................84  
10.9  Publications .............................................................................................................84  
11 Study Management ...........................................................................................................85  
11.1  Monitoring ..............................................................................................................85  
11.1.1  External Data Monitoring Committee  .....................................................85  
11.1.2  Monitoring of the Study ...........................................................................85  
11.1.3  Inspection of Records ..............................................................................85  
11.2  Management of Protocol Amendments and Deviations..........................................86  
11.2.1  Modification of the Protocol ....................................................................86  
11.2.2  Protocol Deviations..................................................................................86  
11.3  Study Termination ...................................................................................................86  
11.4  Final  Report ............................................................................................................87  
12 Reference List ...................................................................................................................88  
13 Appendices .......................................................................................................................91  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 12 13.1  Appendix 1: Schedule of Events .............................................................................91  
13.2  Appendix 2: Contraceptive Guidance .....................................................................95  
13.3  Appendix 3: Liver Function Tests ...........................................................................97  
13.3.1  Liver Function Test Monitoring ...............................................................97  
13.3.2  Considerations for Temporary Discontinuation of Study Drug ...............97  
13.3.3  Permanent Discontinuation of Study Drug ..............................................98  
13.3.4  Re-initiation of Study Drug .....................................................................99  
13.4  Appendix 4: Rome IV Criteria for Functional Heartburn and Functional Dyspepsia
 .......................................................................................................................100  
13.4.1  Functional Heartburn  .............................................................................100  
13.4.2  Functional Dyspepsia .............................................................................100  
13.4.2.1  Postprandial Distress Syndrome ............................................................101  
13.4.2.2  Epigastric  Pain  Syndrome ......................................................................101  
13.5  Appendix 5: Protocol Amendments ......................................................................103  
13.5.1  Protocol Amendment 1  ..........................................................................103  
 
List of Tables  
Table 2 -1 Primary Objectives and Endpoints.................................................................. 27  
Table  2-2  Secondary Objectives and Endpoints.............................................................. 27  
Table  5-1  Excluded Medications and Treatments ........................................................... 49  
Table  6-1  Definitions of Heartburn Severity (Daytime/Nighttime) for the Screening, 
Run-In, and Safety Follow-up Periods............................................................ 52  
Table  6-2  Medically Significant Adverse Event List  ...................................................... 55  
Table  6-3  Adverse Events of Special Interest List  .......................................................... 56  
Table 6 -4 Protocol- Required Safety Laboratory Assessments  ................................................ 68  
Table 13 -1 Schedule of Events .......................................................................................... 92  
Table  13-2  Abnormal Liver Function Criteria For Permanent Discontinuation of Study Drug  ................................................................................................................ 98
 
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 13 List of Figures  
Figure 3-1  Study Scheme.................................................................................................. 31  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 14 Protocol Synopsis  
Protocol 
Number:  NERD -201 
Title:  A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the 
Efficacy and Safety of Vonoprazan 10 mg, 20 mg, and 40 mg Compared to Placebo for Relief of Episodic Heartburn in Subjects with Symptomatic 
Non-Erosive Gastroesophageal Reflux Disease  
Sponsor:  Phathom Pharmaceuticals, Inc.  
2150 East Lake Cook Road, Suite 800 
Buffalo Grove, IL 60089 USA 
Study Phase:  2 
Study Sites:  Approximately 65 sites in the United States  
Indication:  Patients with symptomatic NERD  
Rationale: Gastroesophageal reflux disease (GERD) is prevalent globally and 
represents one of the most common gastrointestinal diseases. The Montreal definition of GERD is a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. The term GERD covers a spectrum of conditions, including non- erosive 
gastroesophageal reflux disease (NERD), erosive esophagitis (EE), and Barrett‚Äôs esophagus. When defining GERD as the presence of at least weekly heartburn and/or regurgitation, epidemiological studies reported prevalence estimates of 18.1% to 27.8%, 8.8% to 25.9%, and 2.5% to 7.8% in North America, Europe, and East Asia, respectively. 
V onoprazan belongs to a new class of acid-inhibitory agents called 
‚Äúpotassium-competitive acid blockers‚Äù and is being developed in the United States and Europe for healing of all grades of EE and relief of heartburn, maintenance of healing of all grades of EE and relief of heartburn, and treatment of Helicobacter pylori  infection.  
V onoprazan at doses from 10 mg to 40 mg has been shown in both single and multiple repeat -dosing studies to have a rapid onset of action after the 
first dose and near maximal effect on pH holding time within 24 hours of dosing, which is maintained with multiple dosing. It is believed that this pharmacologic profile may make it an optimum agent for the treatment of NERD utilizing an ‚ÄúOn -Demand‚Äù dosing scheme. This study will evaluate 
the safety and effectiveness of vonoprazan 10 mg, 20 mg, and 40 mg to treat episodic heartburn in patients with symptomatic NERD after an 
initial 20 mg vonoprazan dose in an  open -label Run -In Period.  
 
   
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 15 Objectives:  Primary  
‚Ä¢ To assess the efficacy of vonoprazan (10 mg, 20 mg, and 40 mg 
On-Demand) compared to placebo (On-Demand) in relief of episodic 
heartburn over 6 weeks in subjects with symptomatic NERD. 
‚Ä¢ To assess the safety of vonoprazan (10 mg, 20 mg, and 40 mg On-Demand) compared to placebo (On-Demand) in subjects with 
symptomatic NERD.  
Secondary  
‚Ä¢ To assess the use of study medication and rescue antacid in subjects treated with vonoprazan (10 mg, 20 mg, and 40 mg On-D emand) 
compared to placebo (On- Demand) over the On -Demand Treatment 
Period. 
Study 
Population: Subjects aged 18 years of age or older with symptomatic NERD 
confirmed by endoscopy. 
Key Inclusion and Exclusion Criteria  
Run-In Period  
Main Inclusion Criteria:  
‚Ä¢ The subject identified their main symptom as heartburn, a burning sensation in the retrosternal area (behind the breastbone). 
‚Ä¢ History of episodes of heartburn for 6 months or longer prior to screening.  
‚Ä¢ Heartburn reported on 4 or more days during any 7 consecutive 
days in the Screening Period as recorded in the electronic diary. 
Main Exclusion Criteria:  
‚Ä¢ Endoscopically confirmed EE.  
‚Ä¢ The subject has active irritable bowel syndrome or had a flare of 
IBS requiring therapy within the prior 6 months. 
‚Ä¢ The subject has a history of, or is suspected of having, functional 
upper gastrointestinal disorders such as functional dyspepsia or 
functional heartburn diagnosed by the Rome IV criteria. 
On-Demand Treatment Period  
Main Inclusion Criteria:  
‚Ä¢ The subject has s table disease, ie, no heartburn in the last 7 days of 
the Run-In Period. 
‚Ä¢ The subject completes the Run -In Period and continues to fulfill 
all eligibility criteria for the Run -In Period (except heartburn 
inclusion criteria).  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 16 ‚Ä¢ Subject completes at least 80% o f diary entries over the Run -In 
Period, including 80% of the entries for the last 7 days.  
Study 
Design:  This is a Phase 2, multicenter, double-blind study of vonoprazan versus 
placebo assessing the relief of episodic heartburn. Subjects with symptomatic NERD (as confirmed by endoscopy) and heartburn symptoms will receive open -label vonoprazan 20 mg once daily (QD) for 
4 weeks. Subjects with stable disease (ie, no heartburn on the last 7 days of the Run-In Period) will be randomized to receive vonoprazan 10 mg, 20 mg, 40 mg or placebo On-Demand for 6 weeks. Subjects will complete an electronic diary to assess presence and severity of heartburn symptoms and use of rescue antacid (if needed) in all periods. During the On-Demand Treatment Period, a more detailed diary will also document 
time of study drug administration and when heartburn relief occurs.  
The study will include 4 periods: 
Screening Period:  Subjects will provide informed consent and undergo 
screening assessments to determine study eli gibility (including endoscopy 
to confirm absence of EE). Subject will have to discontinue proton pump 
inhibitors and histamine-
2 receptor antagonists during this period. 
Study- supplied rescue antacid will be allowed if needed. Subjects will 
complete an ele ctronic diary to assess presence and severity of heartburn 
symptoms and use of rescue antacid. If all eligibility criteria are met, the subject will enter the Run -In Period.  
Run-In Period:  Subjects with symptomatic NERD whose eligibility is 
confirmed will receive open -label vonoprazan 20 mg QD for 4 weeks to 
treat heartburn. Study-supplied rescue antacid will be allowed if needed. Subjects will complete an electronic diary to assess presence and severity of heartburn symptoms and use of rescue antacid.  On-Demand Treatment Period:  Subjects who have stable disease (ie, no 
heartburn on the last 7 days of the Run-In Period) and are compliant with the diary and study medication will be randomized to receive either vonoprazan 10 mg, 20 mg, or 40 mg or placebo On-Demand (but no more than 1 dose within 24 hours) for 6 weeks to treat episodic heartburn. Study- supplied rescue antacid will be allowed 3  hours after taking study 
medication if needed. Subjects will complete an electronic diary to assess presence and severity of heartburn symptoms and use of rescue antacid. In addition, a more detailed diary will also document time of study drug administration and when heartburn relief occurs. Subjects will be contacted by phone weekly during the first 3 weeks to assess th eir 
understanding of diary instructions and On-Demand dosing and to emphasize the importance of completing the diary assessments.  
Follow- up Period:  A safety follow- up visit will occur 1 week after 
completing the On -Demand Treatment Period to assess adverse  events 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 17 (AEs) and serum gastrin. Study -supplied rescue antacid will be allowed if 
needed. Subjects will complete an electronic diary to assess presence and 
severity of heartburn symptoms and use of rescue antacid. 
Estimated 
Study Duration: The total duration of the study is up to 16 weeks. Screening Period is up to 5 weeks, the Run-In Period is 4 weeks, and the On- Demand Treatment 
Period is 6 weeks. A follow-up visit will occur 1 week after completing the On -Demand Treatment Period. 
Efficacy Assessments:  Primary Endpoints  
‚Ä¢ The percentage of evaluable
(a) heartburn episodes completely relieved 
within 3 hours and with no further heartburn reported for 24 hours after taking study drug
 (b) 
 
(a) An evaluable heartburn episode is an episode for which study drug 
was taken and for which the subject completed at least one entry in 
the heartburn episode diary. 
(b) For a heartburn episode to be considered completely relieved, a 
subject must not have taken rescue antacid within 3 hours of taking study drug. 
Secondary Endpoints  
‚Ä¢ The percentage of evaluable heartburn episodes completely relieved within 3 hours after taking study drug 
‚Ä¢ The percentage of evaluable heartburn episodes for each subject that are completely relieved within 3 hours and with no further heartburn reported for 24 hours after taking study drug 
‚Ä¢ The mean number of tablets of rescue antacid taken per day over the On-Demand Treatment Period  
‚Ä¢ The percentage of subjects with complete relief of heartburn within 
3 hours after the first episode and with no further heartburn reported 
for 24 hours after taking study drug 
‚Ä¢ The percentage of days study drug was taken over the On-Demand Treatment Period  
‚Ä¢ The percentage of 24 -hour heartburn- free days over the On -Demand 
Treatment Period  
Safety 
Assessments:  Safety will be assessed by the following: 
‚Ä¢ AEs 
‚Ä¢ Laboratory test values (hematology, serum chemistry, urinalysis); serum gastrin and pepsinogen I/II levels 
‚Ä¢ Electrocardiograms (ECGs)  
‚Ä¢ Vital signs  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 18 Study Drug, 
Dosage, and 
Route of Administra -
tion: Open -label vonoprazan 20 mg Q D will be taken during the 4 -week 
Run-In Period. Blinded study drug (vonoprazan 10 mg, 20 mg, or 40 mg or placebo) will be taken for the treatment of an On-Demand heartburn episode (only once in a 24-hour period) during the 6- week On -Demand 
Treatment Perio d. Study drug will be taken orally with approximately 
240 mL (8 oz) water. Rescue antacid will be provided.  
Sample Size:  The sample size for the On -Demand Treatment Period is calculated based 
on the following assumptions: 
‚Ä¢ Subjects will be randomized to receive either vonoprazan 10 mg, 20 mg, or 40 mg or placebo with a randomization ratio of 1:1:1:1. 
‚Ä¢ Each subject experiences at least 4 evaluable heartburn episodes.  
‚Ä¢ Comparison between each dose of vonoprazan to placebo will be performed using the Fisher‚Äôs Exact test.  
‚Ä¢ A clinically relevant difference of 15% between each dose of vonoprazan and placebo in the proportion of evaluable heartburn episodes completely relieved within 3 hours and with no further heartburn reported for 24 hours after taking study drug. 
Based on these assumptions, a sample size of 200 heartburn episodes per treatment group (or 50 subjects with at least 4 heartburn episodes per treatment group) provides at least 80% statistical power at the 0.05 significance level. During the study if less than 200 subjects are projected to enroll into the On-Demand Treatment Period, additional subjects may be enrolled into the Run-In Period to ensure that a sufficient number of subjects enroll into the On- Demand Treatment Period.  
Assuming 60% of subjects at the end of the Run-In Period do not meet the eligibility criteria for the On -Demand Treatment Period, approximately 
500 subjects will be enrolled into the Run-In Period to achieve 200 subjects for the On- Demand Treatment Period .  
Statistical 
Methods:  Efficacy Analyses  
Primary Efficacy Endpoint  
The percentage of evaluable heartburn episodes completely relieved within 3 hours and with no further heartburn reported for 24 hours after taking study drug will be compared between each dose of vonoprazan and placebo using Fisher‚Äôs Exact test for the Intent- to-Treat (ITT) On -Demand 
set. 
 
Secondary Efficacy Endpoint  
All secondary endpoints will be analyzed for the ITT On- Demand set.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 19   The following secondary endpoints will be compared for each dose of 
vonoprazan to placebo using Fisher‚Äôs Exact test: 
‚Ä¢ The percentage of evaluable heartburn episodes completely relieved 
within 3 hours after taking study drug. 
‚Ä¢ The percentage of subjects with complete relief of heartburn within 3 hours after the first episode and with no further heartburn reported for 24 hours after taking study drug. 
The following secondary endpoints will be compared for each dose of vonoprazan to placebo using a Wilcoxon rank- sum test: 
‚Ä¢ The percentage of evaluable heartburn episodes for each subject that are completely relieved within 3 hours and with no further heartburn reported for 24 hours after taking study drug. 
‚Ä¢ The percentage of days study drug was taken over the On-Demand 
Treatment Period.  
‚Ä¢ The mean number of tablets of rescue antacid taken per day over the 
On-Demand Treatment Period.  
‚Ä¢ The percentage of 24 -hour heartburn-free days during the On- Demand 
Treatment Period.  
Safety Analyses  
Safety will be summarized separately for the Run -In Period and the 
On-Demand Treatment Period. For each period, safety will be assessed by 
summarizing the incidence of AEs and changes in clinical laboratory tests, gastrin and pepsinogen I/II levels, ECGs, and vital signs. 
 
Version and 
Date of 
Protocol: Version 2.0, Amendment 1; 1 6 July 2021 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 20 List of Abbreviations  
Abbreviation  Definition  
AE adverse event  
ALT alanine aminotransferase  
AST  aspartate aminotransferase 
CFR  Code of Federal Regulations 
CONSORT  Consolidated Standards of Reporting Trials 
ECG  electrocardiogram  
eCRF  electronic case report form  
EE erosive esophagitis  
EMA  European Medicines Agency 
EPS epigastric pain syndrome 
FDA Food and Drug Administration 
FSH follicle stimulating hormone  
GCP  Good Clinical Practice  
GERD gastroesophageal reflux disease 
GGT  gamma -glutamyl transferase  
H2RA histamine -2 receptor antagonist 
HBsAg  hepatitis B surface antigen  
hCG human chorionic gonadotropin 
HCV hepatitis C virus  
HIV human immunodeficiency virus 
IBS irritable bowel syndrome 
ICF informed consent form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee 
INR international normalized ratio  
IRB Institutional Review Board  
IRT interactive response technology  
ITT intent -to-treat 
LFT liver function test 
MedDRA  Medical Dictionary for Regulatory Activities  
NERD non-erosive gastroesophageal reflux disease 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 21 Abbreviation  Definition  
PAGI -QoL Patient Assessment of Upper Gastrointestinal Disorders -Quality of Life  
PAGI -SYM  Patient Assessment of Gastrointestinal Disorders -Symptom Severity 
Index  
PD pharmacodynamic(s)  
PDS postprandial distress syndrome 
PPI proton pump inhibitor 
PT preferred term  
PTE pretreatment adverse event  
QD once daily  
SAE  serious adverse event  
SAP statistical analysis plan  
SOC  system organ class  
SoE schedule of events  
SUSAR  suspected unexpected serious adverse reaction  
TEAE treatment -emergent adverse event  
ULN  upper limit of normal 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 22 Summary of Changes 
Protocol Amendment History and Reasons for Amendment 
Version  Date  Reasons for Amendment  
Version 1.0 25 Jan 2021 Original Protocol 
Version 2.0 
(Protocol 
Amendment 1) 16 July 2021 ‚Ä¢ To update the IBS exclusion criterion to exclude 
active IBS or a flare requiring therapy within prior 
6 months 
‚Ä¢ To add 2 telephone contacts at Week 1 and Week 2 
of the On -Demand Treatment Period.  
‚Ä¢ To clarify that compliance with diary and study medication is required for entry into the On-Demand Treatment Period.  
‚Ä¢ To change baseline serum gastrin level to be unblinded during the study. 
‚Ä¢ To increase the number of subjects ex pected to be 
enrolled into the Run-In Period to 500 subjects to 
ensure that a sufficient number of subjects enroll into the On- Demand Treatment Period.  
‚Ä¢ To clarify that use of prescription 
cannabinoids/tetrahydrocannabinol is exclusionary. 
‚Ä¢ To clarify that R un-In failures should undergo 
assessments from the Week 4 Run-In Period. 
 
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 23 1 Introduction  
V onoprazan belongs to a new class of acid-inhibitory agents called ‚Äúpotassium- competitive 
acid blockers‚Äù and is being developed for healing of all grades of erosive esophagitis (EE) 
and relief of heartburn, maintenance of healing of all grades of EE and relief of heartburn, treatment of Helicobacter pylori  infection, and treatment of heartburn in patients with 
symptomatic non-erosive gastroesophageal reflux disease (NERD). 
V onoprazan has been studied in a number of acid- related diseases, including EE healin g and 
maintenance, gastric ulcer/duodenal ulcer healing, and for the prevention of recurrence of a 
gastric or duodenal ulcer during nonsteroidal anti-inflammatory drugs or aspirin 
administration and has received regulatory approval in Japan and other count ries in Asia and 
Latin America for these indications.  
1.1 Study Rationale  
V onoprazan at doses from 10 mg to 40 mg has been shown in both single and multiple 
repeat -dosing studies to have a rapid onset of action after the first dose and near maximal 
effect on p H holding time within 24 hours of dosing, which is maintained with multiple 
doses. It is believed that this pharmacologic profile may make it an optimum agent for the 
treatment of NERD utilizing an ‚Äúon -demand‚Äù dosing scheme. This study will evaluate the 
safety and effectiveness of vonoprazan 10 mg, 20 mg, and 40 mg to treat episodic heartburn 
in patients with symptomatic NERD who have stable disease after treatment with vonoprazan 
20 mg in an open- label Run -In Period. 
1.2 Background  
Gastroesophageal reflux disease (GERD) is prevalent globally and represents one of the most common gastrointestinal diseases. The Montreal definition of GERD is a condition that 
develops when the reflux of stomach contents causes troublesome symptoms and/or 
complications ( Vakil et al 2006). The term GERD covers a spectrum of conditions, including 
NERD, EE, and Barrett‚Äôs esophagus. When defining GERD as the presence of at least weekly heartburn and/or regurgitation, epidemiological studies reported prevalence estimates of 
18.1% to 27.8%, 8.8% to 25.9%, and 2.5% to 7.8% in North America, Europe, and East Asia, 
respectively ( El-Serag et al 2014 ). Proton pump inhibitors (PPIs) are currently the most 
effective available anti -secretory agents for relieving GERD symptoms, healing the injured 
mucosa, and maintaining a healed mucosa ( Freston 2004).  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 24 The 2013 American College of Gastroenterology ‚ÄúGuidelines for the Diagnosis and 
Management of Gastroesophageal Reflux Disease‚Äù recommends that for patients who require 
long- term PPI therapy, PPIs should be administered in the lowest effective dose, including 
on‚Äëdemand or intermittent therapy ( Katz et al 2013 ). On -demand therapy is a self -managed 
therapeutic strategy in which patients take acid -suppressing medications as needed based on 
symptoms of heartburn. Proton pump inhibitors are recommended for treatment of symptomatic NERD for 4 to 8 weeks. None of the PPIs are approved for on-demand therapy in the United States. While esomeprazole and rabeprazole are approved for on-demand treatment of symptomatic GERD in Europe, the primary endpoints of these studies that 
support this were based on subject satisfaction with treatment and study discontinuation 
rates, rather than directly measuring relief of active heartburn episodes ( Talley et al 2001 ; 
Talley  et al 2002; Bytzer et al 2004 ). Studies with PPIs have shown that in NERD patients 
the median time to first report of symptom relief takes 2 days and for sustained symptom 
relief 10 to 13 days. This finding is consistent with the known mechanism of action of PPIs, 
in which there is a build-up effect on the inhibition of acid output after repeated daily dosing. Nevertheless, PPIs are still recommended as needed or On -Demand for the treatment of 
GERD ( Katz et al 2013 ). Published systematic reviews and meta‚Äëa nalysis show that the 
on-demand management of NERD with PPIs has been reported to be a favorable approach 
for patients as maintenance treatment for NERD ( Pace et al 2007 ; Khan et al 2018). 
Moreover, patient adherence and satisfaction with on- demand treatment is greater than with 
continuous PPI treatment with the potential to limit the concerns of adverse events (AEs) and reduce the pill burden for patients.  
To date, only over- the-counter histamine -
2 receptor antagonists ( H2RAs) are approved in the 
US for o n-demand treatment of heartburn; however, these agents have their own limitations 
related to having to dose more than once a day, dosing with food, and the development of 
tachyphylaxis upon continued use ( Colin‚ÄëJones 1995).  
In contrast to EE, NERD is mostly viewed as a non- progressive disease and the treatment 
approach is symptom-driven ( Savarino et al 2017). Reflux symptoms do not occur on a daily 
basis in NERD patients, so continuous dosing may not be warranted in these patients. There are limited data ev aluating vonoprazan on-demand in NERD. The available data suggest 
on-demand therapy is potentially an effective alternative to continuous treatment. In a study published by Hoshikawa et al evaluating vonoprazan 20 mg on-demand for NERD, the 
authors concluded that on -demand therapy is as effective as continuous PPI maintenance 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 25 therapy in terms of patient satisfaction and the majority of the patients preferred the 
on-demand approach over continuous maintenance treatment ( Hoshikawa et al 2019). Similar 
results  are reported with PPI treatment, where on -demand therapy was non- inferior to 
continuous, but on-demand also reduced medication usage ( Bayerd√∂rffer et al 2016).  
The pharmacokinetic and pharmacodynamic (PD) profiles of vonoprazan were assessed in multiple s t 
udies, including Study TAK-
438_107, which showed a rapid rise in pH and a dose 
respo
nse for percent time above pH 4. The mean percentage of time above pH  4 on Day 1 for 
vonoprazan 10 mg, 20 mg, and 40 mg was 43%, 63%, and 86%, respectively, and by Day 7 
was 60%, 85%, and 93%, respectively.  
 conducted 2 studies in Japan to evaluate the treatment of heartburn in subjects with 
NERD ( TAK-438/
CCT-201 [ Kinoshita et al 2016]  and V onoprazan -3001 [ Kinoshita et al 
2019] ). Although there was a trend in favor of vonoprazan for the proportion of 
heartburn-free days (primary endpoint) between treatment groups, the difference did not 
reach statistical significance. The learnings from these studies are being applied in the current 
NERD study. Phathom plans to add measures to select an appropriate NERD population and reduce inclusion of functional heartburn patients. Phathom plans to use an electronic diary 
data collection tool to allow timely and accurate capture of patient symptoms. In addition, a 
wider dose range of vonoprazan is being explored than what has been studied in the  Japan program. 
Overal
l, with vonoprazan‚Äôs pharmacological profile of rapid, potent, and sustained elevations 
of gastric pH, vonoprazan offers the potential to be a highly effective treatment option for 
both continuous dosing and on-demand use for the treatment of heartburn in patients with symptomatic NERD.  
1.3 Justification for Dose  
Selection of the vonoprazan 20 mg dose for the Run-In Period and the vonoprazan 10 mg, 20 mg, and 40 mg dose s for the On -Demand Treatment Period of Study NERD-201 is based 
on the following studies: 
‚Ä¢  conducted a 7 -day multiple repeat-dose study in healthy subjects administered 
with vonoprazan 10 mg, 20 mg, 30 mg, and 40 mg. In this study, intragastric pH wa s 
measured for 24 hours before and after receiving the first dose of vonoprazan. On 

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 26 Day 1, vonoprazan quickly raised intragastric pH in a dose-dependent manner with 
10 mg, 20 mg, and 40 mg doses achieving a mean pH of 4 between 2 to 4 hours after 
dosing. T he vonoprazan 40 mg dose maintains pH above 4 for 24 hours after a single 
dose. 
‚Ä¢ A recent study compared vonoprazan 20 mg to lansoprazole 30 mg and famotidine 
20 mg ( Ohkuma et al 2018). Gastric pH was measured for 6 hours after dosing. Over 
this period, the mean pH was similar between vonoprazan (4.30) and famotidine 
(4.45) and both were higher than lansoprazole (2.65).  
Based on the PD profile, vonoprazan 20 mg and 40 mg are more likely to be suitable for 
on-demand dosing; however, Phathom proposes to also assess vonoprazan 10 mg to confirm 
the lowest effective dose.  
To date, the vonoprazan 40 mg once-daily (QD) dose has been evaluated in 248 subjects with 
a maximum duration of 8 weeks. In Phase 2, 3, and 4 studies, the safety of vonoprazan 20 mg 
and 40 mg are comparable.  
The 20 mg dose for the vonoprazan Run- In Period was selected based on the historical data 
from Japan where vonoprazan 20 mg is the recommended daily dose in the healing of EE and 
has also shown to relieve heartburn in these patients ( Ashida et al 2018). While this dose has 
not yet been shown to be effective in NERD as a daily dose, it is considered a safe and logical dose to be selected for the Run-In Period of this study. 
Overall, the proposed doses of vonoprazan 10 mg, 20 mg, and 40 mg are appropriate for this 
Phase 2 study to explore the on-demand use. 
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 27 2 Study Objectives and Endpoints  
2.1 Primary Objectives and Endpoints  
Table 2-1 Primary Objectives and Endpoints  
Objectives  Endpoints  
‚Ä¢ To assess the efficacy of vonoprazan (10 mg, 
20 mg, and 40 mg On- Demand) compared to 
placebo (On -Demand) in relief of episodic 
heartburn over 6 weeks in subjects with 
symptomatic NERD.   ‚Ä¢ The percentage of evaluable(a) heartburn episodes 
completely relieved within 3 hours and with no 
further heartburn reported for 24 hours after 
taking study drug(b) 
‚Ä¢ To assess the safety of vonoprazan (10 mg, 20 mg, 
and 40 mg On -Demand) compared to placebo 
(On-Demand) in subjects with symptomatic 
NERD.  ‚Ä¢ Safety will be assessed by  the following:  
o AEs 
o Laboratory test values (hematology, serum 
chemistry, urinalysis); serum gastrin and pepsinogen I/II levels  
o ECGs  
o Vital signs  
Abbreviations: AEs, adverse events; ECGs, electrocardiograms; NERD, non- erosive gastroesophageal reflux 
disease.  
(a)  An evaluable heartburn episode is an episode for which study drug was taken and for which the subject 
completed at least one entry in the heartburn episode diary.  
(b)  For a heartburn episode to be considered completel y relieved, a subject must not have taken rescue antacid 
within 3 hours of taking study drug.  
 
2.2 Secondary Objectives and Endpoints  
Table  2-2 Secondary Objectives and Endpoints  
Objectives  Endpoints  
‚Ä¢ To assess the use of study 
medication and rescue antacid in 
subjects treated with vonoprazan 
(10 mg, 20 mg, and 40 mg 
On-Demand) compared to placebo 
(On-Demand) over the On -Demand 
Treatment Period.  Secondary:  
‚Ä¢ The percentage of evaluable(a) heartburn episodes completely 
relieved within 3 hours after taking study drug(b) 
‚Ä¢ The percentage of evaluable(a) heartburn episodes for each 
subject that are completely relieved within 3 hours and with no 
further heartburn reported for 24 hours after taking study drug  
‚Ä¢ The mean number of tablets of rescue antacid taken per day over the On -Demand Treatment Period  
‚Ä¢ The percentage of subjects with complete relief of heartburn within 3 hours after the first episode and with no further 
heartburn reported for 24 hours after tak ing study drug  
‚Ä¢ The percentage of days study drug was taken over  the On -
Demand Treatment Period  
‚Ä¢ The percentage of 24 -hour heartburn -free days over the On-
Demand Treatment Period  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 28 Objectives  Endpoints  
 Exploratory : 
 On-Demand Treatment Period  
‚Ä¢ The percentage of evaluable(a) heartburn episodes completely 
relieved within 30 minutes or 1, 1.5, or 2 hours and with no 
further heartburn reported for 24 hours after taking study 
drug(b) 
‚Ä¢ The percentage of evaluable(a) heartburn episodes that are 
completely relieved within  30 minutes or 1, 1.5, or 2 hours 
after taking study drug(b)  
‚Ä¢ The percentage of evaluable(a) heartburn episodes that 
improved at 30 minutes or 1, 1.5, 2, or 3 hours after taking 
study drug(b)  
‚Ä¢ The percentage of episodes for which subjects continue to be heartburn- free after 24 or 48 hours of taking study drug  
‚Ä¢ The percentage of subjects with at least 50%, at least 75%, and 
100% of their evaluable heartburn episodes completely 
relieved within 3 hours with no further heartburn reported for 24 hours after taking study drug
(b) 
‚Ä¢ The percentage of subjects with at least 50%, at least 75%, and 100% of their evaluable heartburn episodes completely relieved within 3 hours after taking study drug
(b) 
‚Ä¢ The percentage of subjects with complete relief of the first episode of  heartburn within 3 hours after taking study drug  
‚Ä¢ The mean number of days between heartburn episodes
(b) 
‚Ä¢ The percentage of days without daytime heartburn over the On-Demand Treatment Period  
‚Ä¢ The percentage of days without nighttime heartburn over the On-Demand Treatment Period  
‚Ä¢ The mean severity of daytime and nighttime heartburn over the On-Demand Treatment Period  
‚Ä¢ The mean severity of nighttime heartburn over On- Demand 
Treatment Period  
‚Ä¢ The mean severity of daytime heartburn over the On -Demand 
Treatment P eriod  
‚Ä¢ The percentage of days without rescue antacid use over the On-Demand Treatment Period  
‚Ä¢ The change from baseline to the end of the On- Demand 
Treatment Period for each subscale and the total score of the PAGI -SYM questionnaire  
‚Ä¢ The change from baseline to the end of the On- Demand 
Treatment Period for each subscale and the total score of the PAGI -QoL questionnaire  
‚Ä¢ The patient global impression of change in GERD symptoms at the end of the On -Demand Treatment Period  
‚Ä¢ The patient global impression of  severity in GERD symptoms 
over the last 7 days of the On- Demand Treatment Period  
‚Ä¢ The percentage of subjects with each dosing preference  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 29 Objectives  Endpoints  
 Run-In Period  
‚Ä¢ The percentage of 24 -hour heartburn -free days over the Run- In 
Period  
‚Ä¢ The percentage of days without daytime heartburn over the 
Run-In Period  
‚Ä¢ The percentage of days without nighttime heartburn over the Run-In Period  
‚Ä¢ The mean severity of daytime and nighttime heartburn over the 
Run-In Period  
‚Ä¢ The mean severity of nighttime heartburn over the Run- In 
Period  
‚Ä¢ The mean severity of daytime heartburn over the Run -In 
Period  
‚Ä¢ The percentage of days without rescue antacid use over the Run-In Period  
‚Ä¢ The change from baseline to the end of the Run- In Period for 
each subscale and the total score of the PAGI- SYM 
questionnaire  
‚Ä¢ The change from baseline to the end of the Run- In Period for 
each subscale and the total score of the PAGI- QoL 
questionnaire  
‚Ä¢ The patien t global impression of change in GERD symptoms at 
the end of the Run -In Period  
‚Ä¢ The patient global impression of severity in GERD symptoms 
over the last 7 days of the Run -In Period  
Abbreviations: GERD, gastroesophageal reflux disease; PAGI -QoL, Patient As sessment of Upper 
Gastrointestinal Disorders -Quality of Life; PAGI -SYM, Patient Assessment of Gastrointestinal 
Disorders -Symptom Severity Index.  
(a) An evaluable heartburn episode is an episode for which study drug was taken and for which the subject 
compl eted at least one entry in the heartburn episode diary.  
(b)  For a heartburn episode to be considered completely relieved, a subject must not have taken rescue 
antacid within 3 hours of taking study drug.  
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  14 Jul2021  
Page 30 3 Investigational Plan  
3.1 Study Design  
This is a Phase 2, multicenter, double-blind study of vonoprazan versus placebo assessing the 
relief of episodic heartburn. Subjects with symptomatic NERD (as confirmed by endoscopy) and heartburn symptoms will receive open-label vonoprazan 20 mg QD for 4 weeks. Subjects 
with stable disease (ie, no heartburn on the last 7 days of the Run- In Period) will be 
randomized to receive either vonoprazan 10 mg, 20 mg, 40 mg or placebo On- Demand for 
6 weeks. Subjects will complete an electronic diary to assess presence and severity of heartburn symptoms and use of rescue antacid (if needed) in all periods. During the 
On-Demand Treatment Period, a more detailed diary will also document time of study drug 
administration and when heartburn relief occurs. 
A schematic diagram o f the overall study design is presented in Figure 3-1. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 31 Figure  3-1 Study Scheme  
 
Abbreviations: QD, once daily  
 
 
   
 
 
    
  
    
 
   
  
 
 
 
  
 
    
  
    
 
    
 
    
 
  
 
  
  
      
   
     
     
    
    
  
 
  
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 32 The study will include 4 periods (see the schedule of events [SoE] in Appendix 1 
[Section  13.1] for details):  
1. Screening Period:  Subjects will provide informed consent and undergo 
screening assessments to determine study eligibility (including endoscopy to 
confirm absence of EE). Study- supplied rescue antacid will be allowed if 
needed. Subjects will complete an electronic diary to assess presence and severity of heartburn symptoms and use of rescue antacid. If all eligibility criteria are met, the subject will be eligible to enter the Run -In Period.  
2. Run-In Period: Subjects with symptomatic NERD whose eligibility is 
confirmed will receive open -label vonoprazan 20 mg QD for 4 weeks. 
Study- supplied rescue antacid will be allowed if needed. Subjects will 
complete an  electronic diary to assess presence and severity of heartburn 
symptoms and use of rescue antacid.  
3. On-Demand Treatment Period:  Subjects who have stable disease (ie, no 
heartburn on the last 7 days of the Run-In Period) and are compliant with the Diary and  study medication will be randomized to receive either vonoprazan 10 
mg, 20 mg, or 40 mg or placebo On-Demand for 6 weeks to treat episodic heartburn. Study drug should only be taken once in a 24-hour period. Study- supplied rescue antacid will be allowed 3  hours after taking study 
medication if needed. Subjects will complete an electronic diary to assess 
presence and severity of heartburn symptoms and use of rescue antacid. In 
addition, a more detailed diary will also document time of study drug administration and when heartburn relief occurs. Subjects will be contacted by phone weekly during the first 3 weeks to assess their understanding of diary 
instructions and On-Demand dosing and to emphasize the importance of 
completing the diary assessments. 
4. Follow-u p Period: A safety follow- up visit will occur 1 week after completing 
the On -Demand Treatment Period to assess AEs and serum gastrin. 
Study- supplied rescue antacid will be allowed if needed. Subjects will 
complete an electronic diary to assess presence and  severity of heartburn 
symptoms and use of rescue antacid.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 33 End-of-study: A subject will be considered to have completed the study if the subject 
completes the safety follow -up visit. 
3.1.1 Rationale of Study Design  
3.1.1.1  Rationale for the Run -In Period  
The Run-In Period is designed: 
‚Ä¢ To mimic clinical practice of first gaining control of the disease and heartburn 
episodes before transitioning to an ‚ÄúOn-Demand‚Äù dosing scheme. 
‚Ä¢ To minimize inclusion of potential functional heartburn patients who do not truly have acid -related NERD prior to randomization. 
‚Ä¢ To emulate the future Phase 3 design that plans to have a Run-In Period for the 
reasons stated above.  
Four weeks of treatment is consistent with the duration of studies for the treatment of 
heartburn and an appropriate duration to identify patients with stable disease. 
3.1.1.2  Rationale for the On -Demand Treatment Period  
On-demand studies with H 2RAs ranged from 2 to 4 weeks in duration. It is anticipated that 
after 4 weeks of continuous treatment with vonoprazan, it may take several days for symptoms to return. Therefore, an On- Demand Treatment Period of 6 weeks is deemed an 
appropriate duration for Study NERD-201 to observe a sufficient number of episodes of 
heartburn for this study. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 34 4 Subject Selection and Withdrawal Criteria  
4.1 Selection of Study Population  
This study will be conducted at approximately 65 sites in the United States and will enroll 
approximately 500 subjects in the Run-In Period to allow randomization of approximately 200 subjects (approximately 50 subjec ts per arm) in the On -Demand Treatment Period.  
Deviations from the inclusion and exclusion criteria will not be allowed since they can potentially jeopardize the scientific integrity of the study, regulatory acceptability, or subject safety. Therefore, adh erence to the criteria as specified in the protocol is essential.  
4.1.1 Selection for Run -In Period  
4.1.1.1  Inclusion Criteria for Run -In Period  
Subjects are eligible for enrollment in the Run -In Period of the study if they meet all of the 
following inclusion criteria: 
1. The subject is ‚â•18 years of age at the time of informed consent signing. 
2. In the opinion of the investigator or subinvestigators, the subject is capable of understanding and complying with protocol requirements. 
3. The subject signs and dates a written informed consent form (ICF) and any 
required privacy authorization prior to the initiation of any study procedures. 
The subject is informed of the full nature and purpose of the study, including possible risks and side effects. The subject has the ability to cooperate with the 
investigator. Ample time and opportunity should be given to read and 
understand verbal and/or written instructions. 
4. The subject identified their main symptom as heartburn, a burning sensation in the retrosternal area (behind the breastbone).  
5. History of episodes of heartburn for 6 months or longer prior to screening. 
6. Heartburn reported on 4 or more days during any 7 consecutive days in the Screening Period as recorded in the electronic diary.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 35 7. A female subject of childbearing potential who is or may be sexually active 
with a nonsterilized male partner agrees to routinely use adequate 
contraception from the signing of informed consent until 4 weeks after the last dose of study drug as detailed in Appendix 2 ( Section  13.2) of thi
 s pr
otocol. 
4.1.1.2  Exclusion Criteria for Run -In Period  
Subjects are not eligible for study participation in the Run-In Period of the study if they meet any of the following exc lusion criteria:  
1. Endoscopically confirmed EE during the Screening Period assessed by the investigator. Endoscopy should be performed after subjects meet Inclusion 
Criteria 6. Any endoscopic confirmation performed in a routine clinical setting 
within 7 days before signing the informed consent is acceptable to use for the purpose of fulfilling the screening requirement. 
2. The subject has active irritable bowel syndrome (IBS) or had a flare of IBS requiring therapy within the prior 6 months. 
3. The subject has a hi story of or is suspected of having functional heartburn 
diagnosed by the Rome IV criteria: ( Appendix 4).  
4. The subject has a history of or is suspected of having functional dyspepsia diagnosed by the Rome IV criteria ( Appendix 4 ).  
5. The subject has endoscopic Barrett‚Äôs esophagus (>1 cm of columnar-lined esophagus) and/or definite dysplastic changes in the esophagus. 
6. The subject has any other clinically significant condition affecting the esophagus, including eosinophilic esophagitis; esophageal varices; viral or fungal infection; esophageal stricture; a history of radiation therapy, radiofrequency ablation, endoscopic mucosal resection, or cryotherapy to the 
esophagus; or any history of caustic or physiochemical trauma (including 
scler otherapy or esophageal variceal band ligation). However, subjects 
diagnosed with Schatzki‚Äôs ring (mucosal tissue ring around lower esophageal sphincter) or hiatal hernia are eligible to participate.  
7. The subject has scleroderma (systemic sclerosis).  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 36 8. The subject has a history of surgery or endoscopic treatment affecting 
gastroesophageal reflux, including fundoplication and dilation for esophageal 
stricture (except Schatzki‚Äôs ring) or a history of gastric or duodenal surgery (except endoscopic removal of benign polyps). 
9. The subject has an active gastric or duodenal ulcer within 4 weeks before the 
first dose of study drug. 
10. Use of prescription or non-prescription PPIs or H
2RAs throughout the study. 
11. The subject has received vonoprazan in a clinical trial at any ti me or any other 
investigational compound (including those in post- marketing studies) within 
30 days prior to the start of the Screening Period. A subject who has been 
screen failed from another clinical study and who has not been dosed may be considered fo r enrollment in this study.  
12. The subject is a study site employee, an immediate family member, or is in a 
dependent relationship with a study site employee who is involved in the 
conduct of this study (eg, spouse, parent, child, sibling) or who may have consented under duress. 
13. The subject has cutaneous lupus erythematosus or systemic lupus erythematosus. 
14. The subject has had clinically significant upper or lower gastrointestinal bleeding within 4 weeks prior to Screening. 
15. The subject has Zollinger-Ellison syndrome or other gastric acid hypersecretory conditions. 
16. The subject has a history of hypersensitivity or allergies to vonoprazan (including the formulation excipients: D- mannitol, microcrystalline cellulose, 
hydroxypropyl cellulose, fumaric acid, croscarmellose sodium, magnesium stearate, hypromellose, macrogol 8000, titanium oxide, or red or yellow ferric oxide). Skin testing may be performed according to local standard practice to confirm hypersensitivity. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 37 17. The subject has a history of alcohol abuse, illegal drug use, drug addiction, or 
regularly consumes >21 units of alcohol (1 unit = 12 oz/300 mL beer, 
1.5 oz/25 mL hard liquor/spirits, or 5 oz/100 mL wine) per week based on self-report within the 12 months prior to screening. Subjects must have a 
negative urine drug screen for cannabinoids/tetrahydrocannabinol and non-
prescribed medications at screening. Subjects taking prescription drugs (except 
prescription cannabinoids/tetrahydrocannabinol) will be allowed.  
18. The subject is taking any excluded medications or treatments listed in the protocol ( Section  5.9.2).  
19. If female, the subject is pregnant, lactating, or intending to become pregnant before, during, or within 4 weeks after participating in this study, or intending to donate ova during such time period. 
20. The subject has a history or clinical manifestations of significant central 
nervous system, cardiovascular, pulmonary, hepatic, renal, metabolic, other 
gastrointestinal, urological, endocrine, or hematological disease that, in the opinion of the investigator, would confound the study results or compromise 
subject safety.  
21. The subject requires hospitalization or has surgery scheduled during the course 
of the study or has undergone major surgical procedures within 30 days prior to 
the Screening Visit.  
22. The subject has a history of malignancy (including MALToma) or has been treated for malignancy within 5 years prior to the start of the Screening Period (Visit 1). (The subject may be included in the study if he/she has recovered from cutaneous basal cell carcinoma or cervical carcinoma in situ).  
23. The subject has AIDS or human immunodeficiency virus (HIV) infection, or tests positive for the hepatitis B surface an tigen (HBsAg), hepatitis C virus 
(HCV) antibody, or HCV-RNA. However, subjects who test positive for HCV antibody but negative for HCV- RNA are permitted to participate.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 38 24. The subject has any of the following abnormal laboratory test values at the start 
of the Screening Period: 
a) Creatinine levels: >2 mg/dL (>177 Œº mol/L)  
b) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 
>2 √ó the upper limit of normal (ULN) or total bilirubin >2 √ó ULN (except 
subjects with Gilbert Syndrome)  
4.1.1.3  Screen Failures 
Screen failures are defined as subjects who consent to participate in the clinical study but are not subsequently entered in the Run-In Period of the study. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failur e subjects to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal information includes demography, 
screen failure details, eligibility criteria, pretreatment a dverse event (PTE), AEs, and any 
serious adverse events (SAEs).  
If a suspected erroneous laboratory result is obtained at screening, retesting of that laboratory 
parameter will be allowed at investigator discretion with medical monitor approval.  
Subjects m ay be allowed to be rescreened upon discussion with medical monitor.  
4.1.2 Selection for On -Demand Treatment Period  
4.1.2.1  Inclusion Criteria for On -Demand Treatment Period  
Subjects are eligible for enrollment in the On -Demand Treatment Period of the study if they 
meet all of the following inclusion criteria:  
1. The subject completes the Run -In Period, during which the subject was at least 
80% compliant with open-label study drug. 
2. The subject has stable disease, ie, no heartburn the last 7 days of the Run- In 
Period. 
3. The subject continues to fulfill all eligibility criteria for the Run -In Period 
(except Inclusion Criteria 4).  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 39 4. Subject completes at least 80% of diary entries during Run-In Period, including 
80% of diary entries over the last 7 days. 
4.1.2.2  Run-In Failure s 
Run-In failures refer to instances when subjects consent to participate in the clinical study, 
are subsequently entered in the Run-In Period of the study, and do not meet the eligibility 
criteria for the On -Demand Treatment Period. Run- In failures may al so include those 
subjects who withdraw from the study drug or the study ( Section 4.2) during the Run- In 
Period. Run-In failures who do not meet On- Demand entrance eligibility criteria are to 
undergo all applicable Week 4 Run- In Period assessments ( Table 13 -1-Schedule of Events). 
4.1.3 Lifestyle Considerations  
Subjects should be instructed as follows: 
‚Ä¢ To refrain from excessive drinking and eating, an extreme diet change (eg, change to an 
extremely high-fat diet), or excessive exercise throughout the study. 
‚Ä¢ Not to donate blood during the study, and to report on any such donation immediately. 
4.2 Withdrawal of Subjects From Study Drug and/or the Study  
The duration of the study is defined for each subject as the date signed written informed 
consent is provided through the last follow-up visit performed 1 week after completing the 
On-Demand Treatment Period.  
4.2.1 Reasons for Withdrawal/Discontinuation  
Subjects may withdraw from the study at any time (eg, Run-In Period, On- Demand 
Treatment Period) and for any reason without prejudice to their future medical care by the 
investigator or at the study site. Every effort should be made to keep subjects in the study. 
The primary reason for discontinuation or withdrawal of the subject from the study drug or the study should be recorded in the electronic case report form (eCRF). For screen failure subjects, refer to Section  4.1.1.3. For Run-In failure subjects, refer to Section 4.1.2.2. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 40 A subject may be withdrawn from the study for any of the following reasons: 
1. Adverse event or SAE: The subject has experienced a PTE, AE, or SAE that 
requires early termination because continu ed participation imposes an 
unacceptable risk to the subject‚Äôs health, or the subject is unwilling to continue because of the PTE, AE, or SAE. 
Note: If a subject is discontinued from study participation due to a PTE, AE, or SAE, the event will be followed until it is fully resolved or stable.  
2. Liver function test (LFT) abnormalities: Appropriate clinical follow -up 
(including repeat laboratory tests) is to be done until a subject‚Äôs laboratory 
profile has returned to normal/baseline status. See Appendix 3 ( Section 13.3) to 
monitor LFT abnormalities and for the criteria of liver function abnormalities 
for temporary and permanent discontinuation of study drug. 
3. Significant protocol deviation: The discovery post-randomization that the 
subject failed to meet protocol entry criteria or did not adhere to protocol 
requirements, and continued participation poses an unacceptable risk to the subject‚Äôs health.  
4. Lost to follow-up: The subject did not return to the clinic a nd attempts to 
contact the subject were unsuccessful. Attempts to contact the subject must be documented (3 documented telephone contact attempts and 1 certified letter, at a minimum) within 6  weeks of the most recent planned visit. 
5. V oluntary withdrawal: T he subject wishes to withdraw from the study. The 
reason for the withdrawal, if provided, should be recorded in the eCRF. 
Note: All attempts should be made to determine the underlying reason for the withdrawal and, where possible, the primary underlying reason should be 
recorded (ie,  withdrawal due to an AE or lack of efficacy).  
6. Study termination: The sponsor, Institutional Review Boards (IRBs) 
/Independent Ethics Committees (IECs), or regulatory agency terminates the study. 
7. Pregnancy: The subject is found to be pregnant. Note: If the subject is found to be pregnant, the subject must be withdrawn immediately from the treatment. See Section  6.3.2 for furt her instructions on pregnancy. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 41 8. Lack of efficacy: The investigator has determined that the subject is not 
benefiting from investigational treatment and continued participation would 
pose an unacceptable risk to the subject. 
9. Other: The subject is discontinued from the study for any reason other than those listed above. The specific reason(s) for subject discontinuation will be 
recorded in the eCRF where appropriate.  
4.2.2 Handling of Withdrawals  
Subjects are free to withdraw from the study drug or the study at any time upon request.  
Subject participation in the study may be stopped at any time at the discretion of the 
investigator. 
Subjects who discontinue study drug or active participation in the study will no longer 
receive study drug. When a subject withdraws from the study drug or active participation in 
the study, the reason(s) for withdrawal shall be recorded by the investigator on the relevant 
page of the eCRF. Whenever possible, all subjects who discontinue study drug or withdraw from the study prematurely will undergo all end-of-study assessments (subjects who discontinue from the Run-In Period will undergo all Week 4 Run-In Period assessments). 
Subjects who fail to return for final assessments will be contacted by the site to make every 
attempt to comply with the protocol.  
It is vital to obtain follow -up data on any subject withdrawn because of an AE or SAE. In 
every case, efforts must be made to undertake protocol-specified, safety, follow-up 
procedures. 
See the SoE in Appendix 1 ( Section  13.1) for data to be collected at the time of 
discontinuation of study drug and follow-up and for any further evaluations that need to be 
completed.  
The investigator may discontinue a subject‚Äôs study participation at any time during the study when the subject meets the study termination criteria described in Section 4.2.1. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 42 4.2.3 Lost to Follow -up 
A subject  will be considered lost to follow-up if he or she signs the ICF, repeatedly fails to 
return for scheduled visits during the Run- In Period or On -Demand Treatment Period, and is 
unable to be contacted by the study site. 
The following actions must be taken if a subject fails to return to the clinic for a required 
study visit: 
‚Ä¢ The site must attempt to contact the subject and reschedule the missed visit as soon as 
possible, counsel the subject on the importance of maintaining the assigned visit 
schedule, and ascertain whether or not the subject wishes to and/or should continue in the 
study. 
‚Ä¢ Before a subject is deemed lost to follow-up, the investigator or designee must make every effort to regain contact with th e subject (where possible, 3 telephone calls and, if 
necessary, a certified letter [or local equivalent methods] to the subject‚Äôs last known 
mailing address within 6 weeks of most recent planned visit). These contact attempts 
should be documented in the subject‚Äôs medical record.  
‚Ä¢ Should the subject continue to be unreachable, he/she will be considered to have withdrawn from the study due to being lost to follow-up. 
4.2.4 Replacements  
Discontinued or withdrawn subjects will not be replaced. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 43 5 Study Drugs  
5.1 Method of Assigning Subjects to Treatment Groups  
Subjects who meet all of the inclusion criteria and none of the exclusion criteria and have 
symptomatic NERD will initially be dosed during an open- label Run -In Period with 
vonoprazan 20 mg QD for 4 weeks. 
Subjects wi th stable disease (as defined by those who have no heartburn on the last 
7 consecutive days of the Run-In Period) and are compliant with the diary and study 
medication will be randomized using a 1:1:1:1 allocation ratio to receive either vonoprazan 
10 mg, 20 mg, or 40 mg or placebo during the 6- week On -Demand Treatment Period. 
Subjects will be provided study medication on Day -1 of the On- Demand Treatment Period 
and instructed to take their first dose of study medication after experiencing the first 
heartbu rn episode.  
An interactive response technology (IRT) system will be used to administer the randomization schedule. Biostatistics will generate the randomization schedule using SAS software Version 9.4 or later (SAS Institute Inc, Cary, North Carolina) for IRT, which will link sequential subject randomization numbers to treatment codes. The randomization will 
also use an appropriate block size, which will not be revealed. 
5.2 Treatments Administered  
5.2.1 Run-In Period  
‚Ä¢ Open -label study drug (vonoprazan 20 mg QD) to be taken orally for 4 weeks.  
‚Ä¢ Subjects should be instructed as follows: 
To take study drugs with approximately 240 mL (8 oz) water at about the same time 
each day.  
5.2.2 On-Demand Treatment Period  
‚Ä¢ Blinded study drug (vonoprazan 10 mg, vonoprazan 20 mg, vonoprazan 40 mg, or 
placebo) to be taken orally On-Demand for treatment of episodic heartburn. Study 
drug should only be taken once in a 24-hour period. The diary will confirm if 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 44 24 hours has elapsed since the last dose of study drug. The On- Demand Treatment 
Period w ill be 6 weeks.  
‚Ä¢ Subjects should be instructed as follows: 
To take study drug On-Demand with approximately 240 mL (8 oz) water. 
5.3 Rescue Antacid  
‚Ä¢ Up to 12 tablets of Gelusil¬Æ per day (not more than 4 tablets at one time) may be used 
as rescue antacid during the Screening Period, Run-In Period, On- Demand Treatment 
Period, and Safety Follow-up Period.  
‚Ä¢ During the On-Demand Period, rescue antacid should not be taken until 3 hours after 
study drug administration.  
5.4 Identity of Investigational Product and Rescue Antacid  
5.4.1 Vonoprazan and Placebo  
V onoprazan study medication will be supplied as 10-mg, 20-mg, and 40- mg capsules. The 
tablet drug product will be over-encapsulated into Swedish Orange DB- AAel capsules 
containing microcrystalline cellulose at the contract manufacturing organization,  
Rockford, IL, USA. The 40-mg capsule is composed of two 20-mg tablets in one Swedish Orange DB -AAel capsule.  
manufactures the vonoprazan drug substance and tablet drug product. 
The over-encapsulated vonoprazan 10-mg, 20-mg, and 40-mg dose strengths and placebo 
will be identical in appearance. They will be packaged in bottles.  
5.4.2 Rescue Antacid  
Sites will be provided with Gelusil as rescue antacid. The sites will dispense rescue antacid 
on the first day of the Screening Period, and as needed during the Run-In, On- Demand 
Treatment, and Safety Follow-up Periods.  

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 45 5.5 Management of Clinical Supplies 
5.5.1 Study Drug Packaging and Storage  
Over -encapsulated vonoprazan and placebo will be distributed in bottles and shipped by . 
Study supplies must be stored in a secure area (eg, a locked cabinet), protected from 
moisture, and kept at a controlled room temperature (20¬∞C to 25¬∞C [68¬∞F to 77¬∞F]; 
excursions allowed between 15¬∞C and 30¬∞C [59¬∞F to 86¬∞F]) until they are used or returned to 
the sponsor or designee for destruction. Study drug must be stored under the conditions specified on the label and remain in the o riginal container until dispensed. 
Gelusil rescue antacid will be supplied in the original commercial package with a protocol-specific ancillary label and will be shipped by . Gelusil must be stored in a secure area (eg, a locked cabinet) under the conditions specified on the commercial label (below 30¬∞C [86¬∞F]) and remain in the original container until dispensed. 
5.5.2 Test Article and Rescue Antacid Accountability  
The investigator will maintain accurate records of receipt of all test articles, including dates of receipt. In addition, accurate records will be kept regarding when and how much study drug is dispensed and used by each subject in the study. Reasons for departure from the 
expected dispensing regimen must also be recorded. At the completion of the study, to satisfy 
regulatory requirements regarding drug accountability, all study drug will be reconciled and retained or destroyed according to applicable regulations. 
The investigator will maintain accurate records of receipt of all rescue antacid, incl uding 
dates of receipt. In addition, accurate records will be kept regarding when study drug is 
dispensed in the study.  
5.6 Overdose Management  
An overdose is defined as a known deliberate or accidental administration of investigational drug, to or by a study subject, at a dose above that which is assigned to that individual subject according to the study protocol. 
Cases of overdose without manifested signs or symptoms are not considered AEs. Adverse 
events associated with an overdose will be documented on AE eCRF(s) according to 

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 46 Section  6.3.1.3.1. The SAEs associated with overdose should be reported according to the 
procedure outlined in Section  6.3.1.3.2. 
5.6.1 Treatment of Overdose  
In the event of drug overdose, the subject should be treated symptomatically. 
5.7 Blinding  
The study treatment blind will be maintaine d using the IRT. 
A double-blind design is employed so that both the investigators and the subjects will be 
unaware of the treatment assignment during the On- Demand Treatment Period . Moreover, 
study center staff involved in study drug administration and study endpoint assessments,  personnel, and the Phathom team, including the study statistician, will be blinded to the treatment received. The final study report will include all data, including all endpoints after all subjects  have completed the study, the database is locked, and the study is unblinded. 
5.7.1 Breaking the Blind  
The investigational drug blind shall not be broken by the investigator unless information concerning the investigational drug is necessary for the medical treatment of the subject. In the event of a medical emergency, the investigator will be able to access the IRT to determine 
the subject‚Äôs treatment group assignment. The investigator will, whenever possible, discuss 
options with the medical monitor before unblinding. The sponsor must be notified as soon as possible if the investigational drug blind is broken. The date, time, and reason the blind is broken must be recorded in the source documents, and the same information (except the 
time) must be recorded on the eCRF. If an y site personnel are unblinded, administration of 
the investigational drug must be stopped immediately, and the subject must be withdrawn 
from the study. 

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 47 5.8 Study Compliance  
5.8.1 Treatment Compliance  
As subjects will self -administer study drug at home, compliance with study drug is to be 
assessed at each visit. Compliance will be assessed by direct questioning and counting 
returned capsules during the site visits, which will be documented in the source documents 
and eCRF.  
A record of the number of study drug capsules dispensed to and taken by each subject must 
be maintained and reconciled with study drug and compliance records. Treatment start and 
stop dates will be recorded in the eCRF. 
Noncompliance during the Run-In Period is defined as taking less than 80% or more than 
120% of study drug during any evaluation period (visit to visit). Subjects exhibiting poor compliance as assessed by capsule counts should be counseled on the importance of good 
compliance to the study dosing regimen. 
5.8.2 Diary Compliance  
Diary noncompliance during the Run-In Period or On- Demand Treatment Period is defined 
as completing less than 80% of study diary entries. Subjects exhibiting poor compliance as assessed by diary entries should be counseled on the importance of good compliance to the 
study assessments.  
5.9 Prior and Concomitant Therapy  
Any medication or vaccine (including over- the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the subject is receiving at the time of enrollment (or has received within 30 days before the time of enrollment) or receives during the study must be recorded along with the following: 
‚Ä¢ Reason for use 
‚Ä¢ Dates of administration, including start and end dates 
‚Ä¢ Dosage information, including dose and frequency 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 48 Subjects are to be instructed not to take any medications, including over-the-counter 
medications, without first consulting the investigator or subinvestigators. However, 
single-use medications for endoscopic examination and topical medications, including liniments, ophthalmic drops, nasal drops, ear drops, inhaled drugs, adhesive skin patches, and gargle (mouthwash) will be allowed, whether or not they are excluded or restricted. 
Prior use of H
2RAs or PPIs should be documented. The dose and duration and whether or not 
symptoms were relieved  by the medication should be collected.  
The medical monitor should be contacted if there are any questions regarding concomitant or 
prior therapy. 
5.9.1 Background Medications  
Subjects who are being treated with these medications before signing the informed consent, who have no endoscopic evidence of a gastric or duodenal ulcer (see Section  4.1.1.2) during 
the Screening Period, and who are compliant with the dosage as instructed by the medication package insert are permitted to continue, but the dose and administration method are not permitted to change. Switching between QD and once- weekly regimens is permitted for 
drugs containing the same active ingredient: 
‚Ä¢ Bisphosphonates 
‚Ä¢ Antiplatelets (includes low -dose aspirin)  
‚Ä¢ Anticoagulants  
‚Ä¢ Psychotropics  
‚Ä¢ Antidepressants  
‚Ä¢ Methotrexate  
‚Ä¢ Nonsteroidal anti-inflammatory drugs 
Corticosteroids are permitted for the subjects who are using them before signing the ICF at start of the Screening Period, but the dose and administration will not be changed during the 
study. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 49 5.9.2 Excluded Medications  
A list of excluded medications is provided in Table  5-1 
Table  5-1 Excluded Medications and Treatments  
Excluded Medications and Treatments  Beginning of 
Exclusion  End of 
Exclusion  
Other investigational drugs or drugs administered 
due to participation in another clinical trial  30 days prior to start of 
Screening Period Follow- up Visit 
Antacids (except study -supplied Gelusil)  Screening Period  Follow -up Visit  
H2RAs Screening Period Follow- up Visit 
PPIs Screening Period Follow- up Visit 
Strong inhibitors or inducers of CYP3A4 (eg, 
itraconazole, ketoconazole, indinavir, nelfinavir, 
ritonavir, saquinavir, telithromycin)  14 days prior to Run- In 
Period Day 1 End of On-
Demand 
treatment  
CYP3A4 substrates with a narrow therapeutic index  14 days prior to Run -In 
Period Day 1 End of On -
Demand 
treatment  
Surgical procedures that could affect gastric acid 
secretion (eg, any form of partial gastrectomy, 
vagotomy) 30 days prior to Run- In 
Period Day 1 Follow- up Visit 
Other agents affecting digestive organs, including 
muscarinic antagonists (eg, hyoscyamine), 
prokinetics, oral anticholinergic agents, 
prostaglandins, bismuth, sucralfate  30 days prior to Run -In 
Period Day 1 Follow -up Visit  
Atazanavir sulfates; rilpivirine hydrochloride 
(contraindicated with vonoprazan) 5 days prior to Run -In 
Period Day 1 Follow- up Visit 
Abbreviations: CYP, cytochrome P450 isoenzyme; H 2RA, histamine -2 receptor antagonist; PPI, proton pump 
inhibitor.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 50 6 Study Assessments and Procedures  
Prior to undergoing any protocol- specific procedures or assessments, all potential subjects 
must sign and date the ICF. Subjects will have the opportunity to have any questions 
answered before signing the ICF. The investigator must address all questions raised by the subject. The investigator or designee will also sign and date the ICF. 
Study procedures and their timing are summarized in the SoE ( Section 13.1). Adherence to 
the study design requirements, including those specified in the SoE, is essential and required 
for study conduct. Protocol waivers or exemptions are not allowed. Immediate safety concerns should be discussed with the sponsor immediately upon occurrence or awareness to 
determine if the subject should continue or discontinue study drug. All screening evaluations 
must be completed and reviewed to confirm that potential subjects meet all eligibility criteria . 
The investigator will maintain a screening log to record details of all subjects screened and to 
confirm eligibility or record reasons for screening failure, as applicable. 
6.1 Endoscopy  
During the Screening Period, an endoscopy will be performed on all subjects to document the 
absence of EE. The screening endoscopy should be performed after the subject has fulfilled 
all other admission criteria (including diary) and will be assessed by the investigator. Any 
endoscopic confirmation performed in a routine clinical setting within 7 days before signing the informed consent is acceptable to use for the purpose of fulfilling the screening requirement.  
6.2 Efficacy Assessments  
6.2.1 Electronic Diary  
Subjects will be given an electronic diary on the first day of the Screening Period. During the 
Screening, Run-In, and Safety Follow-up Periods subjects will complete the morning and 
evening Heartburn Diary and Rescue Antacid Diary. During the On- Demand Treatment 
Period, subjects will complete the heartburn episode diary, including the Timed Heartburn Assessments and Rescue Antacid Diary. Subjects must bring the electronic diary device to 
each site visit for the investigator to verify Run -In and On-Demand diary eligibility criteria 
and to move the subject to the appropriate period within the electronic diary device, as noted 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 51 in the eDiary Vendor User Manual. Subjects must return the devices that have been assigned 
to them upon completion/termination from the study.  
6.2.1.1  Morning and Evening Heartburn Diary  
During the Screening Period, Run-In Period, and Safety Follow-up Period, subjects will 
document the presence and severity of daytime and nighttime heartburn symptoms twice 
daily in their diary. If the subject experiences no heartburn on any given day, they should also 
provide this information. The electronic diary should be completed every morning upon waking (to record the previous evening's heartburn episode and severity rating) and every evening before bedtime (to record that day's heartburn episode and severity rating). 
6.2.1.2  Rescue Antacid Diary  
During all periods of the study, subjects will record the use of rescue antacid, including the time and number of tablets taken.  
6.2.1.3  On-Demand Heartburn Episode Diary 
During the On-Demand Treatment Period, subjects will document episodes of heartburn experienced and the use of On -Demand study medication as they occur. On days that a 
subject has not reported an episode of heartburn, subjects will also be reminded every 
morning and every evening to record any unrecorded heartburn episodes (no longer than the 
prior day) OR to document that they have not had any heartburn episodes. 
6.2.1.4  On-Demand Heartburn Timed Assessments  
Once heartburn is reported and the subject is eligible to take study medication (ie, 24 hours since the last administration), the diary will be programmed to collect the heartburn episode assessments for 3 hours in order to assess when heartburn relief occurs. The diary will prompt responses 30 minutes after study drug administration is reported and then 1, 1.5, 2, 
and 3 hours after study drug treatment. On rare occasions, when required, subjects may opt 
out of the timed assessments.  
6.2.1.5  Severity Definitions  
The severity of heartburn will be graded by the subject according to the definitions outlined 
in Table  6-1 for the Screening, Run-In, and Safety Follow-up Periods. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 52 Table  6-1 Definitions of Heartburn Severity (Daytime/Nighttime) for the 
Screening, Run-In, and Safety Follow- up Periods  
Definitions of Daytime Heartburn Severity (Daytime=Awake Time)  
Mild - Occasional heartburn, can be ignored, does not influence daily routine  
Moderate - Heartburn cannot be ignored and/or occasionally influences daily routine  
Severe - Heartburn present most of day and/or regularly influences daily routine 
Very Severe - Constant heartburn and/or markedly influences daily routine 
 
Definitions of Nighttime Heartburn Severity (Nighttime=Sleep Time)  
Mild - Occasional heartburn, can be ignored, does not influence sleep  
Moderate - Heartburn cannot be ignored and/or occasionally influences sleep  
Severe - Heartburn present most of night and/or regularly influences sleep 
Very Severe - Constant heartburn and/or markedly influences sleep  
 
The severity of heartburn will be graded by the subject according to the definitions outlined 
in Table  6-2 for the On -Demand T reatment Period.  
Table  6-2 Definitions of Heartburn Severity for the On -Demand Treatment 
Period  
Mild - Heartburn is present but can be ignored, does not influence daily routine or sleep  
Moderate - Heartburn cannot be ignored and/or occasionally influences daily routine or sleep  
Severe - Heartburn regularly influences daily routine or sleep  
Very Severe - Heartburn markedly influences daily routine or sleep  
 
6.2.2 PAGI -SYM Questionnaire  
During the start of the Run-In Period (Day -1), at the end of the Run-In Period, and at the end 
of the On- Demand Treatment Period, each subject will self -administer a paper version of the 
Patient Assessment of Gastrointestinal Disorders -Symptom Severity Index (PAGI- SYM) 
questionnaire. 
Subjects will record their responses directly on each questionnaire. The data from the 
questionnaires will be entered into the eCRF, and the originals will remain at the site as source documentation. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 53 6.2.3 PAGI -QoL Que stionnaire  
During the start of the Run-In Period (Day -1), at the end of the Run-In Period, and at the end 
of the On- Demand Treatment Period, each subject will self -administer a paper version of the 
Patient Assessment of Upper Gastrointestinal Disorders -Quality of Life (PAGI -QoL) 
questionnaire. 
Subjects will record their responses directly on each questionnaire. The data from the 
questionnaires will be entered into the eCRF, and the originals will remain at the site as source documentation.  
6.2.4 Patient Global Impression of Change Questionnaire  
At the end of the Run-In Period and at the end of the On- Demand Treatment Period, each 
subject will self -administer a paper version of the Patient Global Impression of Change. 
Subjects will record their responses directly  on each questionnaire. The data from the 
questionnaire will be entered into the eCRF, and the originals will remain at the site as source documentation.  
6.2.5 Patient Global Impression of Severity Questionnaire  
At the end of the Run-In Period and at the end of the On -Demand Treatment Period, each 
subject will self -administer a paper version of the Patient Global Impression of Severity. 
Subjects will record their responses directly on each questionnaire. The data from the questionnaire will be entered into the e CRF, and the originals will remain at the site as source 
documentation. 
6.2.6 Patient Preference Questionnaire  
At the end of the On- Demand Treatment Period, each subject will self -administer a paper 
version of the Patient Preference Questionnaire.  
Subjects will record their responses directly on each questionnaire. The data from the questionnaires will be entered into the eCRF, and the originals will remain at the site as source documentation. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 54 6.3 Safety Assessments  
6.3.1 Pretreatment Events and Adverse Event s 
6.3.1.1  Definitions  
6.3.1.1.1  Definitions of Pretreatment Adverse Events  
A PTE is defined as any untoward medical occurrence in a clinical investigation subject who 
has signed informed consent to participate in a study which has occurred prior to administration of any study drug; it does not necessarily have to have a causal relationship with study participation. 
6.3.1.1.2  Definitions of Adverse Events  
An AE is defined as any untoward medical occurrence in a subject enrolled into this study regardless of its causal relationship to study drug. An AE can therefore be an unfavorable sign or symptom, or a disease temporally associated with the use of study drug. 
A treatment -emergent adverse event (TEAE) is defined as any event that occurs after the first 
dose of study drug or any event at baseline that worsens in either intensity or frequency after 
the first dose of study drug in that period. 
6.3.1.1.3  Serious Adverse Events  
An SAE is defined as any untoward medical occurrence at any dose for which the following occurs:   
1. Results in DEATH.  
2. Is LIFE -THREATENING. The term ‚Äúlife -threatening‚Äù refers to an event in which the 
subject was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.  
3. Requires inpatient HOSPITALIZATION or prolongation of existing hospitalization.  
4. Results in persistent or significant DISABILITY/INCAPACITY .  
5. Is CONGENITAL ANOMALY/BIRTH DEFECT.  
6. Is an IMPORTANT MEDICAL EVENT that satisfies any of the following:  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 55 ‚Ä¢ May require intervention to prevent items 1 through 5 above 
‚Ä¢ May include any event or symptoms described in the medically significant AE list 
(Table  6-2) 
‚Ä¢ Exposes the subject to danger, even though the event is not immediately 
life-threatening or fatal or does not result in hospitalization 
Table  6-2 Medically Significant Adverse Event List  
Term  
Acute respiratory failure / acute respiratory distress syndrome  
Torsade de pointes / ventricular fibrillation / ventricular tachycardia 
Malignant hypertension Convulsive seizure agranulocytosis  Aplastic anemia  
Toxic epidermal necrolysis/Stevens -Johnson syndrome  
Hepatic necrosis  
Acute li ver failure  
Anaphylactic shock  
Acute renal failure  
Pulmonary hypertension Pulmonary fibrosis Confirmed or suspected endotoxin shock 
Confirmed or suspected transmission of infectious agent by a medicinal product 
Neuroleptic malignant syndrome / malignant hyperthermia  
Spontaneous abortion / stillbirth and fetal death 
 
The PTEs that fulfill one or more of the serious criteria above are also to be considered SAEs 
and should be reported and followed up in the same manner (see Section  6.3.1.3.2 and 
Section  6.3.1.3.3).  
If a subject is noted to have an ALT or AST value >3 √ó ULN and a total bilirubin value 
>2 √ó ULN, for which an alternative etiology has not been identified, the event should be 
recorded as an SAE and reported as per Section  6.3.1.3.2. The investigator must contact the 
medical monitor for discussion of the relevant subject details and possible alternative etiologies, such as acute viral hepatitis A or B or other acute liver disease or medical history or concurrent medical conditions. Follow-up laboratory tests as described in Section  6.3.3 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 56 must also be performed. In addition, if the LFT increases are SAEs, a Liver Function Test 
Increase Form must be completed and transmitted (see  Appendix 3, Section  13.3).  
6.3.1.1.4  Adverse Event of Special Interest  
An AE of special interest is a noteworthy event for the particular product or class of products 
that a sponsor may wish to monitor carefully. It could be serious or nonserious (eg, hair loss, 
loss of taste, impotence), and could include events that might be potential precursors or 
prodromes for more serious medical conditions in susceptible individuals. 
Adverse events of special interest include any event described in Table  6-3. 
Table  6-3 Adverse Events of Special Interest List  
Term  
Hepatotoxicity  
Severe cutaneous adverse reactions  
Clostridium difficile  infections and pseudomembranous colitis 
Hypergastrinemia 
Bone fracture 
 
For additional details on liver function monitoring see Section 13.3. 
6.3.1.1.5  Additional Points to Consider for PTEs and AEs  
An untoward finding generally may involve the following: 
‚Ä¢ Indicates a new diagnosis or unexpected worsening of a pre-existing condition. 
(Intermittent events for pre -existing conditions or underlying disease should not be 
considered PTEs or AEs.) 
‚Ä¢ Necessitates therapeutic intervention.  
‚Ä¢ Requires an invasive diagnostic procedure. 
‚Ä¢ Requires discontinuation or a change in dose of study drug or a concomitant medication. 
‚Ä¢ Is considered unfavorable by the investigator for any reason.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 57 ‚Ä¢ Is caused by a study procedure (eg, a bruise after blood collection); these events should 
be recorded as a PTE/AE.  
Diagnoses versus signs and symptoms: 
‚Ä¢ Each event is required to be recorded to represent a single diagnosis or disorder using 
standard medical terminology rather than individual symptoms. Accompanying signs 
(including abnormal laboratory values or electrocardiogram [ECG] findings) or 
symptoms should NOT be recorded as additional AEs. If a diagnosis is unknown, sign(s) 
or symptom(s) should be recorded appropriately as a PTE(s) or as an AE(s).  
Laboratory values and ECG findings: 
‚Ä¢ Changes in laboratory values or ECG parameters are only considered to be PTEs or AEs 
if they are judged to be clinically significant (ie, if some action or intervention is required or if the investigator judges the change to be beyond the range of normal physiologic 
fluctuation). A laboratory retest and/or continued monitoring of an abnormal value are not considered an intervention. In addition, repeated or additional noninvasive testing for verification, evaluation, or monitoring of an abnormality is not considered an 
intervention. 
‚Ä¢ If abnormal laboratory values or ECG findings are the result of a pathology for which there is an overall diagnosis (eg, increased creatinine in renal failure), the diagnosis only 
should be reported as a PTE or as an AE. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 58 Pre-existing conditions: 
‚Ä¢ Pre-existing conditions (present at the time of signing informed consent) are considered 
concurrent medical conditions and should NOT be recorded as PTEs or AEs. Abnormal 
findings identified at baseline evaluations and screening assessments (eg, laboratory tests, ECG, endoscopy, or X-rays) should NOT be recorded as PTEs unless related to study procedures. However, if the subject experiences a worsening or complication of a 
concurrent condition, the worsening or complication should be recorded appropriately as 
a PTE (worsening or complication occurs before start of study drug) or an AE (worsening or complication occurs after start of study drug). Investigators should ensure that the 
event term recorded captures the change in the condition (eg, ‚Äúworsening of‚Ä¶‚Äù). 
‚Ä¢ If a subject has a pre-existing episodic condition (eg, asthma, epilepsy), any occurrence of an episode should only be captured as a PTE/AE if the episodes become more 
frequent, serious, or severe in nature, that is, investigators should ensure that the AE term recorded captures the change in the condition from baseline (eg ‚Äúworsening of‚Ä¶‚Äù).  
‚Ä¢ If a subject has a degenerative concurrent condition (eg, cataracts, rheumatoid arthritis), 
worsening of the condition should only be captured as a PTE/AE if occurring to a greater 
extent than that which would be expected. Again, investigators should ensure that the AE term recorded captures the change in the condition (eg, ‚Äúworsening of‚Ä¶‚Äù). 
Worsening of PTEs or AEs: 
‚Ä¢ If the subject experiences a worsening or complication of a PTE after starting 
administration of the  study drug, the worsening or complication should be recorded 
appropriately as an AE. Investigators should ensure that the AE term recorded captures 
the change in the condition (eg, ‚Äúworsening of‚Ä¶‚Äù).  
‚Ä¢ If the subject experiences a worsening or complication of an AE after any change in study 
drug, the worsening or complication should be recorded as a new AE. Investigators 
should ensure that the AE term recorded captures the change in the condition (eg, ‚Äúworsening of‚Ä¶‚Äù). 
‚Ä¢ At each required study visit, all AEs that have occurred since the previous visit or AEs 
that have changed in severity since the previous visit must be recorded in the AE record 
of the eCRF.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 59 Changes in severity of AEs / Serious PTEs: 
‚Ä¢ If the subject experiences change in severity of an AE/seriou s PTE, the event should be 
captured once with the maximum severity recorded. 
Preplanned procedures:  
‚Ä¢ Preplanned procedures that were scheduled prior to signing of informed consent are not 
considered PTEs or AEs. However, if a preplanned procedure is perfor med early (eg, as 
an emergency) due to a worsening of the pre-existing condition, the worsening of the 
condition should be captured appropriately as a PTE or an AE. Complications resulting from any planned procedure should be reported as AEs. 
Elective surg eries or procedures:  
‚Ä¢ Elective procedures performed where there is no change in the subject‚Äôs medical 
condition should not be recorded as PTEs or AEs but should be documented in the 
subject‚Äôs source documents. Complications resulting from an elective surgery should be reported as AEs.  
Insufficient clinical response (lack of efficacy):  
‚Ä¢ Insufficient clinical response, efficacy, or pharmacologic action should NOT be recorded 
as an AE. The investigator must make the distinction between exacerbation of 
pre-existing illness and lack of therapeutic efficacy.  
Overdose: 
‚Ä¢ Any manifested side effects will be considered AEs and will be recorded on the AE page 
of the eCRF.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 60 6.3.1.2  Documenting Adverse Events 
6.3.1.2.1  Assessment of Severity  
The severity or intensity of an AE refers to the extent to which an AE affects the subject‚Äôs 
daily activities. The intensity of the AE will be rated as mild, moderate, or severe using the following criteria:  
Mild:  The event is transient and easily tolerated by the subject.  
Moderate:  The event causes  the subject discomfort and interrupts the subject‚Äôs usual 
activities.  
Severe:  The event causes considerable interference with the subject‚Äôs usual activities.  
 
Changes in the severity of an AE should be documented to allow an assessment of the 
duration of the event at each level of intensity to be performed. Adverse events characterized 
as intermittent do not require documentation of onset and duration of each episode. 
6.3.1.2.2  Assessment of Causality  
The investigator‚Äôs assessment of an AE‚Äôs relationship to study drug is part of the 
documentation process, but it is not a factor in determining what is or is not reported in the 
study. If there is any doubt as to whether a clinical observation is an AE, the event should be 
reported. 
The relationship or association of each AE to study drug(s) will be assessed using the 
following categories: 
Related:  An AE that follows a reasonable temporal sequence from administration of study 
drug (including the course after withdrawal of the drug), or for which possible involvement of the drug cannot be ruled out, although factors other than the study drug, such as underlying diseases, complications, concomitant drugs, and concurrent treatments, may also be responsible. 
Not Related:  
An AE that does not follow a reasonable temporal sequence from administration of a drug and/or that can reasonably be explained by other factors, such as underlying diseases, complications, concomitant drugs, and concurrent 
treatments.  
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 61 6.3.1.2.3  Relationship to Study Procedures  
Relationship (causality) to study procedures should be determined for all PTEs and AEs. 
The relationship should be assessed as related if the investigator considers that there is 
reasonable possibility that an event is due to a study procedure. Otherwise, the relationship should be assessed as not related. 
6.3.1.2.4  Start Date  
The start date of the AE/PTE is the date that the first signs/symptoms were noted by the subject and/or physician. 
6.3.1.2.5  Stop Date  
The stop date of the AE/PTE is the date at which the subject recovered, the event resolved but with sequelae, or the subject died. 
6.3.1.2.6  Frequency  
Episodic AEs/PTE (eg, vomiting) or those which occur repeatedly over a period of consecutive days are considered intermittent. All other events are considered continuous. 
6.3.1.2.7  Action Concerning Study Drug  
‚Ä¢ Drug withdrawn: A study drug is stopped due to the particular AE. 
‚Ä¢ Dose not changed: The particular AE did not require stopping a study drug. 
‚Ä¢ Unknown: Only to be used if it has not been possible to determine what action has been 
taken.  
‚Ä¢ Not applicable: A study drug was stopped for a reason other than the particular AE, eg, the study has been terminated, the subject died, or dosing with the study drug was 
already stopped before the onset of the AE. 
‚Ä¢ Dose interrupted: The dose was in terrupted/held due to the particular AE. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 62 6.3.1.2.8  Outcome 
‚Ä¢ Recovered/resolved: Subject returned to baseline status with respect to the AE/PTE.  
‚Ä¢ Recovering/resolving: The intensity is lowered by one or more stages: the diagnosis or 
signs/symptoms have lessened/improved; the abnormal laboratory value improved but 
has not returned to the normal range or to baseline; or the subject died from a cause other than the particular AE/PTE with the condition remaining ‚Äúrecovering/resolving.‚Äù 
‚Ä¢ Not recovered/not resolved: There is no change in the diagnosis, signs, or symptoms; the 
intensity of the diagnosis, signs/symptoms, or laboratory value on the last day of the 
observed study period has worsened from when it started; is an irreversible congenital anomaly; or the subject died fr om another cause with the particular AE/PTE state 
remaining ‚ÄúNot recovered/not resolved.‚Äù 
‚Ä¢ Resolved with sequelae: Subject recovered from an acute AE/PTE but was left with 
permanent/significant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis). 
‚Ä¢ Fatal: The AEs/PTEs are considered the cause of death.  
‚Ä¢ Unknown: The course of the AE/PTE cannot be followed up due to a hospital change or 
residence change at the end of the subject‚Äôs participation in the study. 
6.3.1.3  Time Period and  Frequency for Collecting AE and SAE 
Information  
6.3.1.3.1  Collection and Reporting of Adverse Events  
Collection of PTEs will commence from the time the subject signs the informed consent to 
participate in the study and continue until the subject is first administer ed study drug or until 
screen failure. For subjects who discontinue the study prior to study drug administration, PTEs are collected until the subject discontinues study participation. Collection of AEs will 
commence from the time that the subject is first administered study drug (Day 1). Routine 
collection will continue until the follow -up visit or withdrawal from the study. 
At each study visit, the investigator will assess whether any subjective AEs have occurred. A 
neutral question, such as ‚ÄúHow have you been feeling since your last visit?‚Äù may be asked. 
Subjects may report AEs occurring at any other time during the study. Subjects experiencing 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 63 a serious PTE must be monitored until the symptoms subside and any clinically relevant 
changes in laboratory values have returned to baseline or there is a satisfactory explanation 
for the change. Nonserious PTEs, related or unrelated to the study procedure, need not be followed up for the purposes of the protocol. All subjects experiencing AEs, whether considered a ssociated with the use of the study drug or not, must be monitored until the 
symptoms subside and any clinically relevant changes in laboratory values have returned to baseline or until there is a satisfactory explanation for the changes observed. 
All PTEs  and AEs will be documented in the PTE/AE page of the eCRF, whether or not the 
investigator concludes that the event is related to the drug treatment. The following 
information will be documented for each event: 
1. Event term  
2. Start and stop date 
3. Severity  
4. Investigator‚Äôs opinion of the causal relationship between the event and administration 
of study drug(s) (related or not related) (not completed for PTEs) 
5. Investigator‚Äôs opinion of the causal relationship to study procedure(s), including the 
details of the suspected procedure 
6. Action concerning study drug (not applicable for PTEs) 
7. Outcome of event  
8. Seriousness 
6.3.1.3.2  Collection and Reporting of Serious Adverse Events  
When an SAE occurs through the AE collection period it should be reported according to the 
following procedure:  
An SAE eCRF must be completed and submitted via Medidata Rave immediately or within 
24 hours of first onset or notification of the event. The information should be completed as 
fully as possible but contain, at a minimum: 
‚Ä¢ A short description of the event and the reason why the event is categorized as serious 
‚Ä¢ Subject identification number 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 64 ‚Ä¢ Investigator‚Äôs name 
‚Ä¢ Name of the study drug(s) 
‚Ä¢ Causality assessment  
If the Medidata Rave system is not functioning for any reason, a paper SAE case report form 
must be completed (in English), signed by the investigator, and faxed to the contact listed below. 
The SAE form should be transmitted within 24 hours to . 
Any SAE
 spontaneously reported to the investigator following the AE collection period 
should be reported to the sponsor if considered related to study participation. Investigators are not obligated to actively seek information regarding new AEs or SAEs after 
conclusion of the study participation. However, if the investigator learns of any SAE, 
including a death, at any time after a subject has been discharged from the study, and he/she considers the event to be reasonably related to the study drug or study participation, the investigator must promptly notify the sponsor. Reporting of serious PTEs will follow the 
proced ure described for SAEs. 
6.3.1.3.3  Follow -up of SAEs  
If information not available at the time of the first report becomes available at a later date, the investigator should update the SAE eCRF and transmit it immediately within 24 hours of 
receipt. Copies of any relevant data from the hospital notes (eg, ECGs, laboratory tests, discharge summary, postmortem results) should be provided, if requested. 

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 65 All SAEs should be followed up until resolution or permanent outcome of the event. The 
timelines and procedure for follow- up reports are the same as those for the initial report.  
6.3.1.3.4  Safety Reporting to Investigators, IRBs or IECs, and Regulatory 
Authorities 
The sponsor designee (contract research organization) will be delegated the responsibility for 
reporting all suspected unexpected serious adverse reactions (SUSARs) and any other 
applicable SAEs to regulatory authorities, including the European Medicines Agency (EMA), investigators, and the IRB/IEC , as applicable, in accordance with national regulations in the 
countries where the study is conducted. Relative to the first awareness of the event by/or further provision to the sponsor or sponsor‚Äôs designee, SUSARs will be submitted to the regulatory authorities as an expedited report within 7 days for fatal and life- threatening 
events and 15 days for other serious events, unless otherwise required by national 
regulations. The sponsor designee will also prepare an expedited report for other safety issues 
where these might materially alter the current benefit -risk assessment o f an investigational 
medicinal product or that would be sufficient to consider changes in the investigational medicinal products. 
6.3.1.4  Regulatory Reporting Requirements for SAEs 
Prompt notification by the investigator to the sponsor/sponsor designee of an SAE i s 
essential so that legal obligations and ethical responsibilities toward the safety of subjects and the safety of a study drug under clinical investigation are met. 
The sponsor/sponsor designee has a legal responsibility to notify both the local regulatory 
authority and other regulatory agencies about the safety of a study drug under clinical investigation. The sponsor/sponsor designee will comply with country-specific regulatory 
requirements relating to safety reporting to the regulatory authority, IRB/IE C, and 
investigators. 
For all studies except those utilizing medical devices, investigator safety reports must be 
prepared for SUSARs according to local regulatory requirements and sponsor policy and 
forwarded to investigators as necessary. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 66 An investigator who receives an investigator safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAEs) from the sponsor will review 
and then file it and will notify the IRB/IEC, if appropriate according to local requirements. 
If there is an increase in unexpected SAEs or if there is a change in the frequency and 
character of expected SAEs based on the known safety profile of vonoprazan, further 
evaluation will be conducted to characterize these events and any impact on benefit/risk. 
Health Authorities will be consulted to agree upon the appropriate action to be taken regarding the conduct of the study, including no change to the protocol, revision of the safety monitoring plan, suspension of enrollment, or discontinuation of the study. 
6.3.2 Pregnancy  
If any subject is found to be pregnant during the study, she should be withdrawn, and any sponsor-supplied drug (vonoprazan active) should be immediately discontinued. If the 
pregnancy occurs during administration of active study drug, eg, after Visit 2 or within 
4 weeks of the last dose of active study drug, the pregnancy should be reported immediately, using a pregnancy notification form, to the contact listed in Section  6.3.1.3.2. Should the 
pregnancy occur during or after administration of blinded drug, the investigator must inform 
the subject of their right to receive treatment information. If the subject chooses to receive 
unblinded treatment information, the individual blind should be broken by the investigator. If the female subject agrees to the primary care physician being informed, the investigator should notify the primary care physician that the subject was participating in a clinical study 
at the time she became pregnant and provide details of the treatment the subject received 
(blinded or unblinded, as applicable). All pregnancies (whether subjects on active study drug or placebo) will be reported using the pregnancy form and will be followed up to final outcome. The outcome, including any premature termination, must be reported to the 
sponsor. An evaluation after the birth of the child will also be conducted. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 67 6.3.3 Laboratory Analyses 
See Table  6-4 for the list of clinical laboratory tests to be performed and the SoE 
(Section  13.1) for the timing and frequency. 
‚Ä¢ The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the eCRF. The laboratory reports must be filed with the source documents. Abnormal laboratory findings 
that are expected with the underlying disease should not be considered clinically significant unless judged by the investigator to be more severe than expected for the subject‚Äôs condition. 
‚Ä¢ All laboratory tests with abnormal values considered clinically significant during 
participation in the study or within 30 days after the last dose of study drug should be 
repeated until the values return to normal or baseline or are no longer considered clinically significant by the investigator or medical monitor.  
o If such values do not return to normal/baseline within a period of time judged 
reasonable by the investigator, the etiology should be identified, and the sponsor 
notified. 
o All pr otocol-required laboratory assessments, as defined in Table 6 -4, must be 
conducted in accordance with the laboratory manual and the SoE. 
ÔÇß If laboratory v alues from non‚Äìprotocol- specified laboratory assessments 
performed at the institution‚Äôs local laboratory require a change in subject 
management or are considered clinically significant by the investigator (eg, SAE, 
AE, or dose modification), then the results must be recorded in the unscheduled 
laboratory eCRF. 
All samples will be collected in accordance with acceptable laboratory procedures. Details of these procedures and required safety monitoring will be provided in the laboratory manual. 
All study -required laboratory assessments will be performed by a central laboratory. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 68 Table 6-4 Protocol- Required Safety Laboratory Assessments  
Laboratory 
Assessments  Parameters  
Hematology  ‚Ä¢ Platelet count 
‚Ä¢ RBC count  
‚Ä¢ Hemoglobin  
‚Ä¢ Hematocrit  
‚Ä¢ RBC indices: MCV, MCH  
‚Ä¢ %Reticulocytes  
‚Ä¢ WBC count with differential: neutrophils, lymphocytes, monocytes, eosinophils, basophils  
Clinical chemistry(a)  ‚Ä¢ Blood urea nitrogen  
‚Ä¢ Creatinine  
‚Ä¢ Total and direct bilirubin  
‚Ä¢ ALT/SGPT  
‚Ä¢ AST/SGOT  
‚Ä¢ Alkaline phosphatase  
‚Ä¢ Total protein  
‚Ä¢ Potassium  
‚Ä¢ Sodium  
‚Ä¢ Calcium  
‚Ä¢ Glucose (fasting)(e)  
‚Ä¢ GGT  
Routine 
urinalysis  ‚Ä¢ Specific gravity, appearance, color  
‚Ä¢ pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase  
‚Ä¢ Microscopic examination (if blood or protein is abnormal)  
Other 
screening tests  ‚Ä¢ FSH if menopause is suspected(b)  
‚Ä¢ Urine drug screen including amphetamines (including methamphetamine), 
barbiturates, benzodiazepines, cannabinoids, cocaine, opiates, methadone, and 
phencyclidine  
‚Ä¢ Serum hCG pregnancy test(c) at Screening Visit 1  
‚Ä¢ Urine hCG pregnancy test(c) at Run- In Period Visit 2, randomization Visit 3, and final 
visit for On -Demand Treatment Period Visit 5  
‚Ä¢ Serology (HIV antibody, HBsAg, and HCV antibody; hepatitis C, viral  load RNA(d) 
[qualitative])  
‚Ä¢ Serum gastrin (fasting 12 hours) and serum pepsinogen I and II levels will also be evaluated as safety/PD biomarkers at Day - 1 of Run- In Period; Week 4 of Run- In 
Period; Week 6 of On- Demand Treatment Period; and safety follow -up visit. Day - 1 
baseline gastrin levels will not be blinded. Gastrin at the Week 4 Run- In, Week 6 
On-Demand treatment, and Safety Follow -up visits  and all pepsinogen I and II results 
will be blinded and will not be reported to investigative sites or other blinded personnel until after the study blind is broken.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 69 Abbreviations: ALT,  alanine aminotransferase; AST,  aspartate aminotransferase; FSH, follicle -stimulating 
hormone; GGT, gamma -glutamyl transferase; HBsAg, hepatitis B surface antigen; hCG, human 
chorionic gonadotropin; HCV , hepatitis C virus; H I V,  human immunodeficiency virus; MCH,  mean 
corpuscular hemoglobin; MCV ,  mean corpuscular volume; PD, pharmacodynamics; RBC, red blood cell; 
SGOT,  serum glutamic -oxaloacetic transaminase; SGPT, serum glutamic- pyruvic transaminase; WBC, 
white blood cell.  
(a)  See Section  13.3 for the appropriate guidance on reporting of abnormal liver function tests. For liver 
function test monitoring, see Section 13.3.1. For temporary and permanent discontinuation of study 
drugs  due to abnormal liver function tests, see Section 13.3.2 and Section 13.3.3, respectively. 
(b) Required only for confirmation of postmenopausal females  as defined in Section 13.2 (Appendix 2) . 
Women whose duration of (consecutive) amenorrhea is borderline or open to doubt and where the 
investigator believes the subject to be menopausal by history should have confirmatory FSH drawn.  
(c)  As needed for women of childbearing potential. During the Run- In Period and On- Demand Treatment 
Period, serum pregnancy test will be performed if the urine pregnancy test is posit ive. 
(d)  Reflex - if hepatitis C positive.  
(e) 8 hours fasting at Screening Visit 1 . 
 
Investigators must document their review of each laboratory safety report. 
6.3.4 Physical Examinations  
Refer to the SoE ( Section  13.1) for the timing and frequency for full and brief physical 
examinations, as well as height and weight.  
A complete physical examination will include, at a minimum, assessments of the 
cardiovascular, respiratory, gastrointestinal and neurological systems. Height and weight will 
also be measured and recorded. 
A brief physical examination will include, at a minimum, assessments of the skin, lungs, 
cardiovascular system, and abdomen (liver and spleen). 
Investigators should pay special attention to clinical signs related to previous serious 
illnesses.  
6.3.5 Vital Signs  
Refer to the SoE ( Section  13.1) for the timing and frequency of vital sign assessments.  
Vital signs will include body temperature (oral, temporal, or tympanic measurement), sitting 
blood pressure (resting more than 5 minutes), and heart rate (beats per minute).  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 70 6.3.6 Electrocardiograms  
Refer to the SoE ( Section  13.1) for the timing and frequency of ECG assessments.  
A standard 12- lead ECG will be recorded. The investigator (or a qualified observer at the 
investi gational site) will interpret the ECG using one of the following categories: within 
normal limits, abnormal but not clinically significant, or abnormal and clinically significant. 
The following parameters will be recorded on the eCRF from the subject‚Äôs ECG trace: heart 
rate, PR interval, RR interval, QT interval, QTcF (derived)  and QRS interval. A copy of the 
ECG trace should be kept with the subject‚Äôs notes. For ECG results printed on thermal paper, nonthermal paper copies should be made to avoid degradation of trace over time. 
6.4 Safety Monitoring Committee  
Not applicable.  
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 71 7 Statistical and Analytical Plan  
This section describes the statistical and analytical methods to be used for the study. A 
statistical analysis plan (SAP) will provide details of the statis tical methods and definitions 
for the analysis of efficacy and safety endpoints. To preserve the integrity of the statistical analysis and study conclusions, the SAP will be finalized before database lock. 
7.1 Sample Size Calculations  
The sample size for the O n-Demand Treatment Period is calculated based on the following 
assumptions: 
‚Ä¢ Subjects will be randomized to receive either vonoprazan 10 mg, 20 mg, or 40 mg or 
placebo with a randomization ratio of 1:1:1:1. 
‚Ä¢ Each subject experiences at least 4 evaluable hear tburn episodes.  
‚Ä¢ Comparison between each dose of vonoprazan to placebo will be performed using the Fisher‚Äôs Exact test.  
‚Ä¢ A clinically relevant difference of 15% between each dose of vonoprazan and placebo in the proportion of evaluable heartburn episodes completely relieved within 3 hours and with no further heartburn reported for 24 hours after taking study drug.  
Based on these assumptions, a sample size of 200 heartburn episodes per treatment group (or 
50 subjects with at least 4 heartburn episodes per treatment group) provides at least 80% statistical power at the significance level of 0.05. During the study if less than 200 subjects 
are projected to enroll into the On-Demand Treatment Period, additional subjects may be 
enrolled into the Run-In Period to ensure that a sufficient number of subjects enroll into the On-Demand Treatment Period.  
Assuming 60% of subjects at the end of the Run- In Period do not meet the eligibility criteria 
for the On -Demand Treatment Period, a total of  approximately 500 subject s will be enrolled 
into the Run-In Period to achieve 200 subjects for the On- Demand Treatment Period.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 72 The hypothesis testing is as follows: 
Null Hypothesis  H 0: Pvono = P placebo  
Alternative Hypothesis H a: Pvono ‚â† P placebo  
where P is the proportion of heartburn episodes. 
7.2 Analysis Sets 
The following analysis sets will be used in the statistical analysis.  
7.2.1 All Subjects Set  
All Subjects set consists of all eligible subjects who enrolled into the Run -In Period. 
7.2.2 Safety Sets  
All safety endpoints will be reported for the Run-In and On- Demand Treatment Periods 
separately using the Safety set of each period. For the Run-In Period, the primary and 
secondary endpoints will be reported for the Safety Run- In set.  
Safety Run -In Set  
The Safety Ru n-In set includes subjects in the All Subjects set who received at least one dose 
of study drug (vonoprazan 20 mg) during the Run-In Period. 
Safety On -Demand Set  
The Safety On -Demand set includes all subjects in the Safety Run -In set who were 
randomized and treated at least one heartburn episode with randomized treatment during the 
On-Demand Treatment Period.  
7.2.3 Intent -to-Treat Set  
All efficacy endpoints (primary, secondary, and exploratory) will be analyzed for the On-Demand Treatment Period for the Intent -to-Treat (ITT) On -Demand set.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 73 Intent -to-Treat On -Demand Set  
The ITT On -Demand set includes all subjects in the Safety Run -In set who were randomized 
and completed at least one heartburn episode diary during the On- Demand Treatment Period.  
7.3 Description of Sub groups  
The primary endpoint, the percentage of evaluable heartburn episodes completely relieved 
within 3 hours and with no further heartburn reported for 24 hours after taking study drug, 
will be analyzed by subgroup using the primary analysis method.  
The subgroups are: 
‚Ä¢ age category, years (<45, ‚â•45 - <65, ‚â•65 - <75, ‚â•75)  
‚Ä¢ sex (male, female)  
‚Ä¢ baseline body mass index (BMI) category, kg/m2 (<25, ‚â•25 - <30, ‚â•30)  
‚Ä¢ mean heartburn severity during the Screening Period (mild, moderate, severe, very 
severe)  
7.4 Statistical Analysis Methodology  
For the On-Demand Treatment Period, each treatment comparison of vonoprazan 10 mg, 20 mg, and 40 mg to placebo will be tested at the 0.05 significance level.  
An evaluable heartburn episode is an episode for which study drug was taken and for which 
the subject completed at least one entry in the heartburn episode diary. For a heartburn episode to be considered completely relieved, a subject must not have taken rescue antacid 
within 3 hours of taking study drug. 
Continuous variables will be summarized using the mean, standard deviation, median, 
minimum value, and maximum value. Categorical variables will be summarized using frequency counts and percentages. Statistical analysis of all endpoints, primary, secondary, 
and exploratory, will be described in detail in the SAP. Statistical analysis will be performed 
using SAS software Version 9.4 or later. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 74 No adjustments will be made for multiple comparisons given the exploratory nature of this 
study. 
7.4.1 Efficacy Analyses  
7.4.1.1  Primary Efficacy Endpoint  
The primary endpoint of the percentage of evaluable heartburn episodes completely relieved within 3 hours and with no further heartburn reported for 24 hours after taking study drug 
will be compared between each dose of vonoprazan and placebo using Fisher‚Äôs Exact test for the ITT On -Demand set.  
A sensitivity analysis of the primary endpoint will be performed by including heartburn episodes with rescue antacid use within 3 hours after taking study drug as completely relieved.  
7.4.1.2  Secon dary Efficacy Endpoint  
All secondary endpoints will be analyzed for the ITT On-Demand set and compared for each dose of vonoprazan to placebo.  
The following secondary endpoints will be compared for each dose of vonoprazan to placebo 
using Fisher‚Äôs Exact t est. 
‚Ä¢ The percentage of evaluable heartburn episodes completely relieved within 3 hours 
after taking study drug. 
‚Ä¢ The percentage of subjects with complete relief of heartburn within 3 hours after the first episode and with no further heartburn reported for 24 hours after taking study 
drug. 
The following secondary endpoints will be compared for each dose of vonoprazan to placebo using a Wilcoxon rank- sum test.  
‚Ä¢ The percentage of evaluable heartburn episodes for each subject that are completely 
relieved within 3  hours and with no further heartburn reported for 24 hours after 
taking study drug. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 75 ‚Ä¢ The percentage of days study drug was taken over the On- Demand Treatment Period. 
‚Ä¢ The mean number of tablets of rescue antacid taken per day over the On-Demand 
Treatment Per iod. 
‚Ä¢ The percentage of 24 -hour heartburn- free days over the On -Demand Treatment 
Period. 
7.4.1.3  Exploratory Endpoints On -Demand Treatment Period  
The exploratory endpoints will be analyzed for the ITT On- Demand set. The analysis of 
exploratory endpoints will be described in detail in the SAP. These endpoints are: 
‚Ä¢ The percentage of evaluable heartburn episodes completely relieved within 
30 minutes or 1, 1.5, or 2 hours and with no further heartburn reported for 24 hours 
after taking study drug. 
‚Ä¢ The percentage of eval uable heartburn episodes that are completely relieved within 
30 minutes or 1, 1.5, or 2 hours after taking study drug.  
‚Ä¢ The percentage of evaluable heartburn episodes that improved at 30 minutes or 1, 1.5, 
2, or 3 hours after taking study drug. 
‚Ä¢ The percent age of episodes for which subjects continue to be heartburn- free after 24 
or 48 hours of taking study drug. 
‚Ä¢ The percentage of subjects with at least 50%, at least 75%, and 100% of their evaluable heartburn episodes completely relieved within 3 hours with no further 
heartburn reported for 24 hours after taking study drug. 
‚Ä¢ The percentage of subjects with at least 50%, at least 75%, and 100% of their 
evaluable heartburn episodes completely relieved within 3 hours after taking study drug. 
‚Ä¢ The percentage of subjects with complete relief of the first episode of heartburn within 3 hours after taking study drug. 
‚Ä¢ The mean number of days between heartburn episodes. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 76 ‚Ä¢ The percentage of days without daytime heartburn over the On- Demand Treatment 
Period.  
‚Ä¢ The percentage of days without nighttime heartburn over the On- Demand Treatment 
Period.  
‚Ä¢ The mean severity of daytime and nighttime heartburn over the On- Demand 
Treatment Period.  
‚Ä¢ The mean severity of nighttime heartburn over On- Demand Treatment Period.  
‚Ä¢ The mean severity of daytime heartburn over the On- Demand Treatment Period.  
‚Ä¢ The percentage of days without rescue antacid use over the On -Demand Treatment 
Period.  
‚Ä¢ The change from baseline to the end of the On- Demand Treatment Period for each 
subscale and  the total score of the PAGI -SYM questionnaire. 
‚Ä¢ The change from baseline to the end of the On- Demand Treatment Period for each 
subscale and the total score of the PAGI -QoL questionnaire. 
‚Ä¢ The patient global impression of change in GERD symptoms at the end of the 
On-Demand Treatment Period.  
‚Ä¢ The patient global impression of severity in GERD symptoms over the last 7 days of the On -Demand Treatment Period. 
‚Ä¢ The percentage of subjects with each dosing preference.  
7.4.1.4  Exploratory Endpoints Run -In Period  
The exploratory endpoints will be analyzed for the Safety Run-In set. The analysis of 
exploratory endpoints will be described in detail in the SAP. These endpoints are: 
‚Ä¢ The percentage of 24 -hour heartburn- free days over the Run -In Period.  
‚Ä¢ The percentage of days without daytime heartburn over the Run-In Period.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 77 ‚Ä¢ The percentage of days without nighttime heartburn over the Run-In Period.  
‚Ä¢ The mean severity of daytime and nighttime heartburn over the Run-In Period.  
‚Ä¢ The mean severity of nighttime heartburn over the Run-In Period.  
‚Ä¢ The mean severity of daytime heartburn over the Run-In Period.  
‚Ä¢ The percentage of days without rescue antacid use over the Run-In Period.  
‚Ä¢ The change from baseline to the end of the Run-In Period for each subscale and the 
total score of the PAGI -SYM questionnaire. 
‚Ä¢ The change from baseline to the end of the Run-In Period for each subscale and the total score of the PAGI -QoL questionnaire. 
‚Ä¢ The patient global impression of change in GERD symptoms at the end of the Run- In 
Period.  
‚Ä¢ The patient global impression of severity in GERD symptoms over the last 7 days of the Run-In Period. 
7.4.2 Safety Analyses  
Safety will be summarized separately for the Run -In Period and the On- Demand Treatment 
Period. For each period, safety will be assessed by summarizing the incidence of AEs and 
changes in clinical laboratory tests, gastrin and pepsinogen I/II levels, ECGs and vital signs. For the Run-In Period, baseline will be the last assessment on or before the date of first dose 
of study drug in the Run-In Period. For the On- Demand Treatment Period, baseline will be 
the last assessment on or before the date of randomizat ion.  
Adverse Events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). The number and percentage of subjects experiencing TEAEs (see definition in 
Section 6.3.1.1.2) will be summarized by MedDRA system organ class (SOC) and preferred 
term (PT) overall, by severity, and by relationship to study drug for the Run-In and On-Demand Treatment Periods for each treatment group. Sepa rate summaries will also be 
generated for treatment -related AEs overall and by severity.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 78 For tabulations of TEAE frequency, if a subject has more than 1 episode of the same event, 
the subject will be counted only once for that event. If a subject has more than 1 TEAE that is 
coded to the same PT, the subject will be counted only once for that PT. If a subject has more than 1 TEAE within an SOC, the subject will be counted only once for that SOC. In the tabulation of TEAE frequency by maximum intensity, a subject will be counted only once 
using the highest severity for each PT and SOC. 
Clinical laboratory tests, pepsinogen I/II levels, gastrin levels, and vital signs will be 
summarized with descriptive statistics at each visit by treatment group. A summary of  change 
from baseline at each visit will also be summarized by treatment group.  
7.4.3 Other Analyses 
For the Run- In Period, demographics and other baseline characteristics will be summarized 
overall and by treatment group using the Safety Run-In set. For the On- Demand Treatment 
Period, demographics and other baseline characteristics will be summarized overall and by treatment group using the ITT On- Demand and Safety On -Demand sets.  
Summary statistics (N, mean, median, standard deviation, and range) will be gener ated for 
continuous variables (eg, age and weight). The number and percentage of subjects will be 
presented for categorical variables (eg, sex, race).  
7.4.4 Interim Analyses 
No interim analyses will be performed.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 79 8 Data Quality Assurance  
This study will be conducted according to the International Council for Harmonisation (ICH) 
E6(R2) risk and quality processes described in the applicable procedural documents. The quality management approach to be implemented in this study will be documented and will comply with th e current ICH guidance on quality and risk management (DHHS 2018). The 
sponsor assumes accountability for actions delegated to other individuals (eg, contract research organizations).  
8.1 Data Management  
As part of the responsibilities assumed by participating  in the study, the investigator agrees to 
maintain adequate case histories for the subjects treated as part of the research under this protocol. The investigator agrees to maintain accurate eCRFs and source documentation as part of the case histories. These source documents may include diary cards, laboratory 
reports, and ECG strips.  
Investigative site personnel will enter subject data into electronic data capture. The analysis 
data sets will be a combination of these data and data from other sources (eg, laboratory data).  
Clinical data management will be performed in accordance with applicable sponsor‚Äôs standards and data cleaning procedures to ensure the integrity of the data, eg, removing errors and inconsistencies in the data. Adverse event terms will be coded using the MedDRA, and concomitant medications will be coded using the World Health Organization Drug Dictionary 
(WHODRUG).  
After database lock, each study site will receive a CDROM containing all of their 
site-specific eCRF data as entered into Med idata Rave for the study, including full 
discrepancy and audit history. Additionally, a CDROM copy of all of the study site‚Äôs data 
from the study will be created and sent to the sponsor for storage.  will maintain a 
duplicate CDROM copy for their records. In all cases, subject initials will not be collected or transmitted to the sponsor. 

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 80 9 Ethics 
9.1 Independent Ethics Committee or Institutional Review Board  
Federal regulations, national regulations, and the ICH guidelines require that approval be 
obtained from an IRB/IEC before participation of human subjects in research studies. Before study onset, the protocol, informed consent, advertisements to be used for the recruitment of 
study subjects, and any other written information regarding this study to be provided to the 
subject must be approved by the IRB/IEC. Documentation of all IRB/IEC approvals and of the IRB/IEC compliance with ICH Good Clinical Practice (GCP) will be maintained by the 
site and will be available for review by the sponsor or its designee. 
All IRB/IEC approvals should be signed by the IRB/IEC chairman or designee and must 
identify the IRB/IEC name and address, the clinical protocol by title or protocol number or both, and the date approval or a favorable opinion was granted. 
The investigator is responsible for providing written summaries of the progress and status of 
the study at intervals not exceeding 1 year or otherwise specified by the IRB/IEC. The investigator must promptly supply the sponsor or its designee, the IRB/IEC, and, where applicable, the institution, with written reports on any changes significantly affecting the 
conduct of the study or increasing the risk to subjects. 
9.2 Ethical Conduct of the Study  
The study will be performed in accordance with the ethical principles that have their origin in 
the Declaration of Helsinki, ICH GCP, the protocol, and all applicable regulations. 
9.3 Subject Information and Consent  
A written informed consent in compliance with respective regulatory authority regulations shall be obtained from each subject before entering the study or performing any unusual or 
nonroutine procedure that involves risk to the subject. An informed consent template may be 
provided by the sponsor to investigative sites. If any institution- specific modifications to 
study- related procedures are proposed or made by the site, the consent should be reviewed by 
the sponsor or its designee or both before IRB/IEC submission. Once reviewed, the consent 
will be submitted by the investigator to his or her IRB/IEC for review and approva l before 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 81 the start of the study. If the ICF is revised during the course of the study, all active 
participating subjects must sign the revised form. 
Before recruitment and enrollment, each prospective subject will be given a full explanation 
of the study and be allowed to read the approved ICF. Once the investigator is assured that the subject understands the implications of participating in the study, the subject will be 
asked to give consent to participate in the study by signing the ICF. 
The investigator shall retain the signed original ICF(s) and give a copy of the signed original 
form to the subject. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 82 10 Investigator‚Äôs Obligations  
The following administrative items are meant to guide the investigator in the conduct of the 
study but may be subject to change based on industry and government standard operating procedures, working practice documents, or guidelines. Changes will be reported to the IRB/IEC but will not result in protocol amendments.  
10.1 Confidentiality  
All laboratory specimens, evaluation forms, reports, and other records will be identified in a manner designed to maintain subject confidentiality. All records will be kept in a secure 
storage area with limited access. Clinical information will not be released without the written 
permission of the subject, except as necessary for monitoring and auditing by the sponsor, its designee, the US Food and Drug Administration (FDA) or any regulatory authority(ies), or the IRB/IEC.  
The investigator and all employees and coworkers involved with this study may not disclose or use for any purpose other than performance of the study any data, record, or other unpublished, confidential information disclosed to those individuals for the purpose of the study. Prior written agreement from the sponsor or its designee must be obtained for the 
disclosure of any said confidential information to other parties. 
10.2 Financial Disclosure and Obligations  
Investigators are required to provide financial disclosure information to allow the sponsor to 
submit the complete and accurate certification or disclosure statements required under 
21 Code of Federal Regulations (CFR) 54. In addition, the investigator must provide to the 
sponsor a commitment to promptly update this information if any relevant changes occur during the course of the investigation and for 1 year following the completion of the study. 
Neither the sponsor nor  is financially responsible for further testing or treatment of any 
medical condition that may be detected during the screening process. In addition, in the absence of specific arrangements, neither the sponsor nor  is financially responsible for 
further treatment of the subject‚Äôs disease.  

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 83 10.3 Investigator Documentation  
Prior to beginning the study, the investigator will be asked to comply with ICH E6 8.2 and 
Title 21 of the CFR by providing the following essential documents, including but not limited 
to the following: 
‚Ä¢ IRB/IEC approval 
‚Ä¢ Original investigator -signed investigator agreement page of the protocol 
‚Ä¢ Form FDA 1572, fully executed, and all updates on a new fully executed Form 
FDA 1572 for US sites and equivalent form for non- US sites  
‚Ä¢ Curriculum vitae for the investigator and each subinvestigator listed on Form FDA 1572 or equivalent form for non- US sites  
‚Ä¢ Financial disclosure information to allow the sponsor t o submit complete and accurate 
certification or disclosure statements required under 21 CFR 54. In addition, the investigators must provide to the sponsor a commitment to promptly update this 
information if any relevant changes occur during the course of the investigation and for 1 year after the completion of the study. 
‚Ä¢ IRB/IEC -approved informed consent, samples of site advertisements for recruitment for 
this study, and any other written information regarding this study that is to be provided to the subject 
‚Ä¢ Laboratory certifications and normal ranges for any local laboratories used by the site, in 
accordance with 42 CFR 493 
10.4 Study Conduct  
The investigator agrees that the study will be conducted according to the principles of 
ICH E6. The investigator will conduct all aspects of this study in accordance with all 
national, state, and local laws or regulations. Study information from this protocol will be posted on publicly available clinical trial registers before enrollment of subjects begins. 
10.5 Adherence to Prot ocol 
The investigator agrees to conduct the study as outlined in this protocol in accordance with ICH E6 and all applicable guidelines and regulations. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 84 10.6 Adverse Events and Study Report Requirements  
By participating in this study, the investigator agrees to submit reports of SAEs to the 
sponsor and/or IRB/IEC according to the timeline and method outlined in the protocol. In addition, the investigator agrees to submit annual reports to the study site IRB/IEC as appropriate. 
10.7 Investigator‚Äôs Final Report  
Upon completion of the study, the investigator, where applicable, should inform the institution; the investigator/institution should provide the IRB/IEC with a summary of the 
study‚Äôs outcome and the sponsor and regulatory authority(ies) with any reports required. 
10.8 Records Retention  
Essential documents should be retained until at least 2 years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or at least 2 years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents should be retained for a longer period, however, if required by the applicable regulatory requirements or by an agreement with the sponsor. It is the responsibility of the sponsor to 
inform the investigator/institution as to when these documents no longer need to be retained. 
10.9 Publications  
After completion of the study, the data may be considered for reporting at a scientific meeting or for publication in a scientific journal. In these cases, the sponsor will be 
responsible for these activities and will work with the investigators to determine how the manuscript is written and edited, the number and order of authors, the publication to w hich it 
will be submitted, and other related issues. The sponsor has final approval authority over all 
such issues.  
Data are the property of the sponsor and cannot be published without prior authorization 
from the sponsor, but data and publication thereof will not be unduly withheld. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 85 11 Study Management  
11.1 Monitoring  
11.1.1  External Data Monitoring Committee  
Not applicable.  
11.1.2  Monitoring of the Study  
The clinical monitor, acting as the main line of communication between the sponsor (or 
designee) and the investigator and as a representative of the sponsor, has the obligation to follow the study closely. In doing so, the monitor will visit the investigator and study site at 
periodic intervals, in addition to maintaining necessary telephone and letter contact. The 
monitor will maintain current personal knowledge of the study through observation, review of study records and source documentation, and discussion of the conduct of the study with the investigator and personnel. 
All aspects of the study will be carefully monitored, by the sponsor or its designee, for 
compliance with applicable government regulation with respect to current GCP and current standard operating procedures. 
11.1.3  Inspection of Records  
Investigators and institutions involved in the study will permit study- related monitoring, 
audits, IRB/IEC review, and regulatory inspections by providing direct access to all study records. In the event of an audit, the investigator agrees to allow the sponsor, representatives 
of the sponsor, or a regulatory agency access to all study records. 
The investigator should promptly notify the sponsor and  of any audits scheduled by any 
regulatory authorities and promptly forward copies of any audit reports received to the sponsor. 

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 86 11.2 Management of Protocol Amendments and Deviations 
11.2.1  Modific ation of the Protocol  
Any changes in this research activity, except those necessary to remove an apparent, 
immediate hazard to the subject, must be reviewed and approved by the sponsor or its designee. Amendments to the protocol must be submitted in writing to the investigator‚Äôs 
IRB/IEC for approval before subjects can be enrolled into an amended protocol. 
11.2.2  Protocol Deviations 
The investigator or designee must document and explain in the subject‚Äôs source documentation any deviation from the approved protocol. The investigator may implement a 
deviation from, or a change of, the protocol to eliminate an immediate hazard to study subjects without prior IRB/IEC approval. As soon as possible after such an occurrence, the implemented deviation or change, the reasons for it, and any proposed protocol amendments 
should be submitted to the IRB/IEC for review and approval, to the sponsor for agreement, 
and to the regulatory authorities, if required. 
A deviation from the protocol is an unintended or unanticipated departure from the 
procedures or processes approved by the sponsor and the IRB/IEC and agreed to by the 
investigator. A significant deviation occurs when there is nonadherence to the protocol by the 
subject or investigator that results in a significant additional risk to the subject. Significant deviations can include nonadherence to inclusion or exclusion criteria, or nonadherence to FDA regulations or ICH GCP guidelines, and will lead to the subject being withdrawn from 
the study ( Section  4.2).   
Protocol deviations will be documented by the clinical monitor throughout the course of 
monitoring visits. Principal investigators will be n otified in writing by the monitor of 
deviations. The IRB/IEC should be notified of all protocol deviations in a timely manner. 
11.3 Study Termination  
Although the sponsor has every intention of completing the study, the sponsor reserves the right to discontinue the study at any time for clinical or administrative reasons.  
The end of the study is defined as the date on which the last subject completes the last visit (includes follow-up visit). 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 87 11.4 Final Report  
Whether the study is completed or prematurely terminated, the sponsor will ensure that the 
clinical study reports are prepared and provided to the regulatory agency(ies) as required by the applicable regulatory requirement(s). The sponsor will also ensure that the clinical study reports in marketing applications meet the standards of the ICH harmonised tripartite 
guideline E3: Structure and content of clinical study reports.  
Where required by applicable regulatory requirements, an investigator signatory will be 
identified for the approval of the clinical study report. The investigator will be provided reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity to review the complete study results. 
Upon completion of the clinical study report, the sponsor will provide the investigator with 
the full summary of the study results. The investigator is encouraged to share the summary 
results with the study subjects, as appropriate. The study results will be posted on publicly 
available clinical trial registers.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 88 12 Reference L ist 
Ashida K, Iwakiri K, Hiramatsu N, Sakurai Y , Hori T, Kudou K, et al. Maintenance for 
healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol. 2018;24(14):1550-61. 
Bayerd√∂rffer E, Bigard MA, Weiss W, Mearin F, Rodrigo L, Dominguez Mu√±oz JE, et al. 
Randomized, multicenter study: on-demand versus continuous maintenance treatment 
with esomeprazole in patients with non-erosive gastroesophageal reflux disease. BMC Gastroenterol. 2016;16:48.  
Bytzer P, Blum A, De Herdt D, Dubois D; Trial Investigators. Six-month trial of 
on-demand rabeprazole 10 mg maintains symptom relief in patients with non- erosive 
reflux disease. Aliment Pharmacol Ther. 2004;20(2):181-8.  
Colin -Jones DG. The role and limitations of H2- receptor  antagonists in the treatment of 
gastro -oesophageal reflux disease. Aliment Pharmacol Ther. 1995;9(suppl 1):9-14. 
Department of Health and Human Services (DHHS), Food and Drug Administration 
(FDA), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: E6(R2) Good Clinical Practice: 
Integrated Addendum to E6(R1) March 2018. [cited 2021 Jan 12] Available from: 
https://www.fda.gov/media/93884/download  
El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of 
gastro -oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871-80. 
Freston JW. Therapeutic choices in reflux disease: defining the criteria for select ing a 
proton pump inhibitor. Am J Med. 2004;117(suppl 5A):14S-22S. Hoshikawa Y , Kawami N, Hoshino S, Tanabe T, Umezawa M, Kaise M, et al. Efficacy of 
on-demand therapy using 20-mg vonoprazan for non-erosive reflux disease. Esophagus. 
2019;16(2):201-6.  
Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of 
gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308-29. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 89 Khan Z, Alastal Y , Khan MA, Khan MS, Khalil B, Shrestha S, et al. On-demand therapy 
with proton pump inhibitor s for maintenance treatment of nonerosive reflux disease or 
mild erosive esophagitis: a systematic review and meta -analysis. Gastroenterol Res Pract. 
2018;2018:6417526. 
Kinoshita Y , Sakurai Y , Shiino M, Kudou K, Nishimura A, Miyagi T, et al. Evaluation of 
the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux 
disease: a Phase III, randomized, double-blind, placebo-controlled, multicenter study. Curr Ther Res Clin Exp. 2016;81-82:1-7.  
Kinoshita Y , Sakurai Y , Takabayashi N, Kudou K, Araki T, Miyagi T, et al. Efficacy and 
safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a 
randomized, placebo-controlled, Phase 3 study. Clin Transl Gastroenterol. 2019;10(11):e00101.  
Ohkuma K, Iida H, Inoh Y , Kanoshima K, Ohkubo H, Nonaka T, et al. Comparison of the 
early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three- way 
crossover study. J Clin Biochem Nutr. 2018;63(1):80-3. 
Pace F, Tonini M, Pallotta S, Molteni P, Porro GB. Syste matic review: maintenance 
treatment of gastro -oesophageal reflux disease with proton pump inhibitors taken 
'on-demand'. Aliment Pharmacol Ther. 2007;26(2):195-204. Rome IV Criteria page. Rome Foundation web site. Available at: 
https://theromefoundation.org/rome- iv/rome -iv-criteria/ . Accessed January 14, 2021. 
Savarino E, de Bortoli N, De Cassan C, Della Coletta M, Bartolo O, Furnari M, et al. The natural history of gastro- esophageal ref lux disease: a comprehensive review. Dis 
Esophagus. 2017;30(2):1-9. 
Talley NJ, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang C, et al. 
Esomeprazole 20 mg maintains symptom control in endoscopy- negative 
gastro -oesophageal reflux disease: a controlled  trial of 'on-demand' therapy for 6 months. 
Aliment Pharmacol Ther. 2001;15(3):347-54.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 90 Talley NJ, Venables TL, Green JR, Armstrong D, O‚ÄôKane KP, Giaffer M, et al. 
Esomeprazole 40 mg and 20 mg is efficacious in the long- term management of patients 
with endoscopy- negative gastro -oesophageal reflux disease: a placebo -controlled trial of 
on-demand therapy for 6 months. Eur J Gastroenterol Hepatol. 2002;14(8):857-63.  
Vakil  N, van Zanten SV , Kahrilas P, Dent J, Jones R; Global Consensus Group. The 
Montreal definition and classification of gastroesophageal reflux disease: a global, 
evidence -based consensus. Am J Gastroenterol. 2006;101(8):1900-20. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 91 13 Appendices  
13.1 Appendix  1: Schedule of Events  
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 94 (c)  The date of first dosing day is defined as Day 1 in both Run- In Period and On -Demand Treatment Period. The date of randomization is defined as Day - 1 
of On -Demand Treatment Period.  
(d)  Subjects should continue to meet inclusion criteria ( Section 4.1.1.1) and exclusion criteria ( Section 4.1.1.2), except Inclusion Criterion  4. 
(e) Full physical examination is performed at Screening; a brief physical examination is performed at all other visits.  
(f) Required only for confirmation of postmenopausal females as described in Section 13.2 (Appendix 2) . Women whose duration of (consecutive) 
amenorrhea is borderline or open to doubt and where the investigator believes the subject to be menopausal by history should have c onfirmatory FSH 
drawn.  
(g)  See Section  6.3.3  and Table 6 -4 for all required laboratory assessments.  
(h)  Gastrin Week 4 Run- In, Week 6 On -Demand treatment and Safety follow -up visits and pepsinogen I and II results will be blinded and will not be rep orted 
to investigative sites or other blinded personnel until the study blind is broken.  
(i)  Only female subjects with childbearing potential. Serum hCG at screening and urine hCG at all subsequent visits.  
(j)  The screening endoscopy can be performed any time during that period; however, it should be performed after the subject has fulfilled all other admission 
criteria. Any endoscopic confirmation performed in a routine clinical setting within 7 days before signing the informed conse nt is acceptable to use for the 
purpose of fulfilling the screening requirement.  
(k)  Subjects should be instructed to complete the electronic diary every morning upon waking (for nighttime symptoms) and every evening before bedtime (for daytime symptoms) on each day of the Screening, Run- In and Follow -up Period. During the On -Demand Treatment Period, subjects will be 
instructed to complete the electronic diary to document heartburn episodes and study drug administration. Rescue antacid use should be reported during 
all period s.  
(l)  Subjects are to start dose administration from Day 1.  
(m)  Rescue antacid will be dispensed as needed after the Screening Period.  
(n)  Sites will document dispensing rescue antacid. Subjects do not need to return unused rescue antacid.  
(o) Day -1 baseline gastrin levels will not be blinded.  
(p) Run -In failure procedures.  
 
 
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 95 13.2 Appendix  2: Contraceptive Guidance  
Contraception Guidance: 
From  signing of informed  consent, throughout the duration of the study, and for 4 weeks  after 
the last dose of study drug, female subjects  of childbearing potential*  who are sexually  active 
with a nonsterilized male partner** must use adequate contraception. In addition, they must 
be advised not to donate ova during this period. 
*Females NOT of childbearing potential are defined as those who have been 
surgically sterilized (hysterectomy, bilateral oophorectomy, or tubal ligation) or who are postmenopausal (eg, defined as at least 1 year since last regular menses with an 
follicle -stimulating hormone (FSH) >40 IU/L or at least 5 years since last regular 
menses, confirmed before any study drug is impl emented).  
**Sterilized males should be at least 1 -year post vasectomy and should have 
confirmed that they have obtained documentation of the absence of sperm in the 
ejaculate.  
Birth Control: Birth control methods considered acceptable for this study include:  
Barrier methods (each time that you have intercourse):  
‚Ä¢ Male condom PLUS spermicide 
‚Ä¢ Cap (plus spermicidal cream or jelly) PLUS male condom and spermicide 
‚Ä¢ Diaphragm (plus spermicidal cream or jelly) PLUS male condom and spermicide  
Intrauterine Devices  
‚Ä¢ Copper T PLUS condom or spermicide 
‚Ä¢ Progesterone T PLUS condom or spermicide 
Hormonal Contraceptives 
‚Ä¢ Implants  
‚Ä¢ Hormone shot/injection 
‚Ä¢ Combined pill 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 96 ‚Ä¢ Minipill  
‚Ä¢ Patch  
‚Ä¢ Vaginal ring PLUS male condom and spermicide 
During the course of the study, serum human chorionic gonadotropin ( hCG)  will be 
performed at Screening and regular urine hCG pregnancy tests will be performed only for 
women of childbearing potential. Subjects will receive continued guidance with respect to the avoidance of pregnancy as part of the study procedures ( Section 13.1). Female subjects 
must have a negative urine hCG pregnancy test on Day -1 prior to study drug dispensation. 
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 97 13.3 Appendix 3: Liver Function Tests  
13.3.1  Liver Function Test Monitoring  
Liver function will be carefully monitored throughout the study. Additional monitoring may be 
necessary and is recommended for subjects with abnormal LFTs. 
If subjects with normal baseline ALT or AST levels experience ALT or AST >3 √ó ULN and a 2 -
fold increase above baseline, follow- up laboratory tests (at a minimum, serum alkaline 
phosphatase, ALT, AST, total bilirubin, gamma-glutamyl transferase (GGT), and international 
normalized ratio [INR]) should be repeated within a maximum of 7 days and preferably within 48 to 72 hours after the abnormality was found. 
If subjects with elevated baseline ALT or AST levels experience ALT or AST >5 √ó ULN, follow -
up laboratory tests (at a minimum, serum alkaline phosphatase, ALT, AST, total bilirubin, GGT, 
and INR) should be repeated within a maximum of 7 days and preferably within 48 to 72 hours after the abnormality was found. 
If subjects with either a normal or elevated baseline ALT or AST levels experience ALT or AST 
>8 √ó ULN, follow-up laboratory tests (at a minimum, serum alkaline phosphatase, ALT, AST, 
total bilirubin, GGT, and INR) should be repeated within a maximum of 48 hours after the abnormality was found. 
13.3.2  Considerations for Temporary Discontinuation of Study Drug  
If the ALT or AST levels remain elevated >3 √ó ULN in subjects with normal baseline ALT or AST levels and a 2 -fold increase above baseline OR  if the ALT or AST levels remain elevated >5 
√ó ULN in subjects with elevated baseline ALT or AST levels on 2 consecutive occasions, the 
investigator must contact the medical monitor to discuss additional testing, recommended 
monitoring, possible temporary discontinuation of study drug, and possible alternative etiologies. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 98 13.3.3  Permanent Discontinuation of Study Drug  
If any of the circumstances occur as mentioned in Table  13-2 at any time during treatment, the 
study drug should be permanently discontinued: 
Table  13-2 Abnormal Liver Function Criteria For Permanent Discontinuation of 
Study Drug  
Subject Baseline Aminotransferases  Criteria for Discontinuation of Study Drug  
Normal or Elevated ALT or AST (all subjects) ‚Ä¢ ALT or AST >8 √ó ULN  
Normal ALT and AST  ‚Ä¢ ALT or AST >5 √ó ULN and persists for more than 
2 weeks  
‚Ä¢ ALT or AST >3 √ó ULN AND a 2-fold increase above 
baseline value in conjunction with elevated total bilirubin >2 √ó ULN or  INR >1.5  
‚Ä¢ ALT or AST >3 √ó ULN AND a 2-fold increase above 
baseline value with appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, 
rash, and/or eosinophilia (>5%)  
Elevated ALT or AST  ‚Ä¢ ALT or AST >5 √ó ULN AND persists for more than 
2 weeks  
‚Ä¢ ALT or AST >5√ó ULN AND in conjunction with elevated 
total bilirubin >2 ULN or INR >1.5  
‚Ä¢ ALT or AST >5 √ó ULN AND appearance of fatigue, 
nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)  
Abbreviations: ALT, a lanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; 
ULN, upper limit of normal  
 
In each of these instances, appropriate clinical follow -up should be instituted (including repeat 
laboratory tests) until a satisfactory conclusion (ie, until the AE resolves, the laboratory value 
returns to baseline, or the condition becomes stable). 
If a subject meets the liver safety criteria and must be discontinued from study drug, the subject 
will continue to be followed per the protocol schedule until the study is completed. If the subject 
refuses to return for the study visits, telephone visits may be conducted; however, this is not 
preferred or recommended. The reason for discontinuation of study drug should be listed as an LFT abnormality.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 99 If any of t he above circumstances occur at any time during the study, the abnormality should be 
documented as an SAE, and a Liver Function Test Increase Form completed and sent to:  
13.3.4  Re-initiation of Study Drug  
If the study drug is discontinued due to any of the scenarios provided above, study drug must not 
be re- initiated without consultation with the medical monitor.  
  

Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 100 13.4 Appendix 4: Rome IV Criteria for Functional Heartburn and Functional 
Dyspepsia  
Rome IV criteria ( 2016) available at https://theromefoundation.org/rome- iv/rome -iv-criteria/.  
13.4.1  Functional  Heartburn 
Functional Heartburn Diagnostic Criteria (Note: criteria fulfilled for the last 3  months with 
symptom onset at least 6 months prior to diagnosis with a frequency of at least twice a week)  
‚Ä¢ Burning retrosternal discomfort or pain 
‚Ä¢ No symptom relief despite optimal antisecretory therapy  
‚Ä¢ Absence of evidence that gastroesophageal reflux (elevated acid exposure time and/or 
symptom reflux association) or EE is the cause of the symptom 
‚Ä¢ Absence of major esophageal motor disorders (Achalasia/esophogastric junction outflow obstruction, diffuse esophageal spasm, jackhammer esophagus, absent peristalsis)  
13.4.2  Functional  Dyspepsia  
Functional dyspepsia must  fulfill criteria  for postprandial dis tress syndrome (PDS;  
Section  13.4.2.1) and/or epigastric  pain  syndrome (EPS;  Section  13.4.2.2) 
 Diagnostic criteria  for Functional Dyspepsia  (Note:  criteria  fulfilled  for the  last 3 months with  
symptom onset at least  6 months prior to  diagnosis) 
 
1. One or more  of the following:  
‚Ä¢ Bothersome postprandial fullness 
‚Ä¢ Bothersome early satiation  
‚Ä¢ Bothersome epigastric pain 
‚Ä¢ Bothersome epigastric burning 
AND  
2. No evidence of structural disease (including at upper endoscopy) that is likely to explain the 
symptoms  
 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 101 13.4.2.1  Postprandial Distress  Syndrome  
Diagnostic criteria  for PDS  (Note:  criteria  fulfilled  for the last 3 months with  symptom onset at 
least  6 months prior to  diagnosis) must  include one or both of the following  at least  3 days a 
week:  
1. Bothersome postprandial fullness (ie, severe enough to impact on usual activities) 
2. Bothersome early satiation (ie, severe enough to prevent finishing a regular size 
meal)  
No evidence of organic, systemic, or metabolic disease that is likely to explain the symptoms on routine investigations (including at upper endoscopy) 
Supportive criteria  
‚Ä¢ Postprandial epigastric pain or burning, epigastric bloating, excessive belching, and nausea can also be present  
‚Ä¢ Vomiting warrants consideration of another disorder 
‚Ä¢ Heartburn is not a dyspeptic symptom but may often co- exist  
‚Ä¢ Symptoms that are relieved by evacuation of feces or gas should generally not be considered as part of dyspepsia 
‚Ä¢ Other individual digestive symptoms or groups of symptoms (eg, from GERD and IBS) m ay co -exist with PDS  
13.4.2.2  Epigastric  Pain  Syndrome  
Diagnostic criteria  for EPS  (Note:  Criteria  fulfilled  for the last 3 months with  symptom onset at 
least  6 months prior to  diagnosis ) must  include one or both of the following  symptoms  at least  
1 day a week:  
 
‚Ä¢ Bothersome epigastric pain (ie, severe enough to have an impact on usual activities) 
‚Ä¢ Bothersome epigastric burning (ie, severe enough to have an impact on usual activities)  
No evidence of organic, systemic, or metabolic disease that is likely to explain the symptoms on routine investigations (including at upper endoscopy).  
Supportive criteria  
‚Ä¢ Pain may be induced by ingestion of a meal, relieved by ingestion of a meal, or may 
occur while fasting  
‚Ä¢ Postprandial epigastric bloating, belching, and nausea can also be present  
‚Ä¢ Persistent vomiting likely suggests another disorder 
‚Ä¢ Heartburn is not a dyspeptic symptom but may often co- exist  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 102 ‚Ä¢ The pain does not fulfill biliary pain criteria  
‚Ä¢ Symptoms that are relieved by evacuation of feces or gas generally should not be 
considered as part of dyspepsia 
‚Ä¢ Other digestive symptoms (such as from GERD and IBS) may co- exist with EPS  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 103 13.5 Appendix 5: Protocol Amendments 
Changes to the protocol text 
In this section, all affected protocol sections are detailed; the sequence of the sections follows the 
structure of the original protocol. Additions to the study protocol are shown in bold and deletions are shown in strike through text. Corrections of obvious typing errors or omissions are not 
highlighted. 
13.5.1  Protocol Amendment 1 
Protocol Synopsis  
Study Population: 
Main Exclusion Criteria : 
‚Ä¢ The subject has active  irritable bowel syndrome or had a flare of IBS requiring 
therapy within the prior 6 months . 
On-Demand Treatment Period (Main Inclusion Criteria) : 
‚Ä¢ The subject has stable disease, ie,  no heartburn in the last 7 days of the Run-In Period. 
‚Ä¢ The subject completes the Run -In Period and continues to meet fulfill all of the inclusion 
and exclusioneligibility  criteria for the Run -In Period (except heartburn inclusion 
criteria).  
Study Design: 
On-Demand Treatment Period : 
Subjects who have stable disease (ie, no heartburn on the last 7 days of the Run- In Period) and 
are compliant with the diary and study medication wi ll be randomized to receive either 
vonoprazan 10 mg, 20 mg, or 40 mg or placebo On-Demand (but no more than 1 dose within 24 
hours) for 6  weeks to treat episodic heartburn. Study-supplied rescue antacid will be allowed 3 
hours after taking study medication if needed. Subjects will complete an electronic diary to 
assess presence and severity of heartburn symptoms and use of rescue antacid. In addition, a 
more detailed diary will also document time of study drug administration and when heartburn 
relief occurs . Subjects will be contacted by phone weekly during the first 3  weeks to assess 
their understanding of diary instructions and On-D emand dosing and to emphasize the 
importance of completing the diary assessments.  
Sample Size:  
Based on these assumptions, a sample size of 200 heartburn episodes per treatment group (or 50 subjects with at least 4 heartburn episodes per treatment group) provides at least 80% statistical 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 104 power at the 0.05 significance level. During the study if less than 200 subjects are projected 
to enroll into the On -Demand Treatment Period, additional subjects may be enrolled into 
the Run- In Period to ensure that a sufficient number of subjects enroll into the On-
Demand Treatment Period.  
Assuming 4060% of subjects at the end of the Run- In Perio d do not meet the eligibility criteria 
for the On -Demand Treatment Period, a total of 334approximately 500 subjects will be enrolled 
into the Run-In Period to achieve 200 subjects for the On- Demand Treatment Period .  
Study Design ( Section 3.1)  
Figure 3-1 w as updated to reflect the subject number changes and the addition of new telephone 
contacts.  
On-Demand Treatment Period:  
Subjects who have stable disease (ie, no heartburn on the last 7 days of the Run- In Period ) and 
are compliant with the Diary and study medication  will be randomized to receive either 
vonoprazan 10 mg, 20 mg, or 40 mg or placebo On-Demand for 6 weeks to treat episodic heartburn. Study drug should only be taken once in a 24-hour period. Study- supplied rescue 
antacid will be allowed 3  hours after taking study medication if needed. Subjects will complete 
an electronic diary to assess presence and severity of heartburn symptoms and use of rescue 
antacid. In addition, a more detailed diary will also document time of study drug administration 
and when heartburn relief occurs. Subjects will be contacted by phone weekly during the first 3 weeks to assess their understanding of diary instructions and On-D emand dosing and to 
emphasize the importance of completing the diary assessments.  
Selection of Study Population ( Section  4.1) 
This study will be conducted at approximately 65 sites in the United States and will enroll approximately 334500 subjects in the Run-In Period to allow randomization of approximately 
200 subjects (ap proximately 50 subjects per arm) in the On- Demand Treatment Period.  
Exclusion Criteria for Run -In Period (Section  4.1.1.2)  
2. The subject has active irritable bowel syndrome (IBS.) or had a flare of IBS requiring 
therapy within the prior 6 months.  
6. The s ubject has any other clinically significant  condition affecting the esophagus, including 
eosinophilic esophagitis; esophageal varices; viral or fungal infection; esophageal stricture; a history of radiation therapy, radiofrequency ablation, endoscopic mucosal resection, or 
cryotherapy to the esophagus; or any history of caustic or physiochemical trauma (including 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 105 sclerotherapy or esophageal variceal band ligation). However, subjects diagnosed with Schatzki‚Äôs 
ring (mucosal tissue ring around lower esophageal sphincter) or hiatal hernia are eligible to 
participate.  
11. The subject has received any vonoprazan in a clinical trial at any time or any other 
investigational compound (including those in post-marketing studies) within 30 days prior to the 
start of the Screening Period. A subject who has been screen failed from another clinical study 
and who has not been dosed may be considered for enrollment in this study. 
14. The subject has had clinically significant upper or lower gastrointestinal bleeding within 
4 weeks prior to randomizationScreening . 
17. The subject has a history of alcohol abuse, illegal drug use, drug addiction, or regularly 
consumes >21 units of alcohol (1 unit = 12 oz/300 mL beer, 1.5 oz/25  mL hard liquor/spirits, or 5 
oz/100 mL wine) per week based on self-report within the 12 months prior to screening. Subjects 
must have a negative urine drug screen for cannabinoids/tetrahydrocannabinol and non-prescribed medications at screening. Subjects taking prescription drugs (except prescription 
cannabinoids/tetrahydrocannabinol)  will be allowed.  
Inclusion Criteria for On -Demand Treatment Period (Section  4.1.2.1)  
2. The subject has stable disease, ie,  no heartburn the last 7 days of the Run-In Period. 
3. The subject continues to meet the inclusion and exclusionfulfill all eligibility criteria for the 
Run-In Period (except Inclusion Criteria 4).  
Run-In Failures (Section  4.1.2.2)  
Run- In failures refer to instances when subjects consent to participate in the clinical study, are 
subsequently entered in the Run-In Period of the study, and do not meet the eligibility criteria for 
the On -Demand Treatment Period. Run-In failures may also include those subjects who 
withdraw from the study drug or the study ( Section 4.2) during the Run- In Period. Run-In 
failures who  do not meet On -Demand entrance eligibility criteria are to undergo all 
applicable Week 4 Run- In Period assessments (Table 13 -1-Schedule of Events).  
Handling of Withdrawals ( Section  4.2.2)  
Subjects who discontinue study drug or active participation in the study will no longer receive study drug. When a subject withdraws from the study drug or active participation in the study, 
the reason(s) for withdrawal shall be recorded by the investigator on the relevant page of the 
eCRF. Whenever possible, all subjects who discontinue study drug or withdraw from the study prematurely will undergo all end-of-study assessments. (subjects who discontinue from the 
Run-In Period will undergo all Week 4 Run -In Period assessments).  Subjects who fail to 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 106 return for final assessm ents will be contacted by the site to make every attempt to comply with 
the protocol.  
Method of Assigning Subjects to Treatment Groups ( Section  5.1) 
Subjects with stable disease (as defined by those who have no heartburn on the last 7 consecutive 
days of the Run- In Period) and are compliant with the diary and study medication will be 
randomized using a 1:1:1:1 allocation ratio to receive either vonoprazan 10 mg, 20 mg, or 40 mg 
or placebo during the 6- week On -Demand Treatment Period. Subjects will be provided study 
medication on Day -1 of the On-Demand Treatment Period and instructed to take their first dose 
of study medication after experiencing the first heartburn episode. 
Treatment Compliance ( Section  5.8.1 ) 
A record of the number of study drug capsules dispensed to and taken by each subject must be maintained and reconciled with study drug and compliance records. Treatment start and stop dates , including dates for delays and/or dose reductions, willalso  be recorded in the eCRF. 
Table 5 -1 Excluded Medications and Treatments  
Excluded Medications and Treatments  Beginning of Exclusion End of Exclusion 
Other investigational drugs or drugs administered 
due to participation in another clinical trial  30 days prior to start of Screening Period Follow- up Visit  
Antacids (except study -supplied Gelusil) Screening Period  Follow- up Visit  
H2RAs Screening Period  Follow- up Visit  
PPIs Screening Period  Follow- up Visit  
Strong inhibitors or inducers of CYP3A4 (eg, itraconazole, ketoconazole, indinavir, nelfinavir, ritonavir, saquinavir, telithromycin) 14 days prior to Run -
In Period Day 1  End of On -
Demand  
treatment  
CYP3A4 substrates with a narrow therapeutic index 14 days prior to Run-
In Period Day 1  End of On-
Demand  
treatment  
Surgical procedures that could affect gastric acid secretion (eg, any form of partial gastrectomy, vagotomy) 30 days prior to Run-
In Period Day 1  Follow-up Visit  
Other agents affecting digestive organs, including 
muscarinic antagonists (eg, hyoscyamine), prokinetics, oral anticholinergic agents, prostaglandins, bismuth, sucralfate 30 days prior to Run-
In Period Day 1  Follow- up Visit  
Atazanavir sulfates; ril pivirine hydrochloride 
(contraindicated with vonoprazan) 5 days prior to Run -
In Period Day 1  Follow- up Visit  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 107 Excluded Medications and Treatments  Beginning of Exclusion End of Exclusion 
Abbreviations: CYP, cytochrome P450 isoenzyme; H 2RA, histamine -2 receptor antagonist; PPI, proton pump 
inhibitor.  
 
Electronic Diary ( Section  6.2.1)  
Subjects will be given an electronic diary on the first day of the Screening Period. During the 
Screening, Run-In, and Safety Follow- up Periods subjects will complete the morning and 
evening Heartburn Diary and Rescue Antacid Diary. During the On- Demand Treatment Period, 
subjects will complete the heartburn episode diary, including the Timed Heartburn Assessments 
and Rescue Antacid Diary. Subjects must bring the electronic diary device to each site visit 
for the investigator to verify Run- In and On-Demand diary eligibility criteria and to move 
the subject to the appropriate period within the electronic diary device, as noted in the 
eDiary Vendor User Manual. Subjects must re turn the devices that have been assigned to 
them upon completion/termination from the study.  
On-Demand Heartburn Episode Diary (Section 6.2.1.3  
During the On-Demand Treatment Period, subjects will document episodes of heartburn experienced and the use of on demand  On-Demand  study medication as they occur. On days 
that a subject has not reported an episode of heartburn, s Subjects will also be expected to 
complete the diary in the reminded every  morning and every  evening to document record any 
unrecorded heartburn episodes (no longer than the prior day) OR to document that they  if 
they have or have not had any heartburn episodes . 
On-Demand Heartburn Timed Assessments (Section  6.2.1.4)  
Once heartburn is reported and the subject is eligible to take study medication (ie, 24 hours since the last administration), the diary will be programmed to collect the heartburn episode assessments for 3 hours in order to assess when heartburn relief occurs. The diary will prompt 
responses 30 minutes after study drug administration is reported and then 1, 1.5, 2, and 3 hours 
after study drug treatment. Subjects will be allowed to On rare occasions, when required, 
subjects may  opt out of the timed assessments. 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 108 Table 6 -4 Protocol -Required Safety Laboratory Assessments  
Laboratory 
Assessments  Parameters  
Hematology  ‚Ä¢ Platelet count 
‚Ä¢ RBC count  
‚Ä¢ Hemoglobin  
‚Ä¢ Hematocrit  
‚Ä¢ RBC indices: MCV, MCH  
‚Ä¢ %Reticulocytes  
‚Ä¢ WBC count with differential: neutrophils, lymphocytes, monocytes, eosinophils, basophils  
Clinical chemistry(a)  ‚Ä¢ Blood urea nitrogen  
‚Ä¢ Creatinine  
‚Ä¢ Total and direct bilirubin  
‚Ä¢ ALT/SGPT  
‚Ä¢ AST/SGOT  
‚Ä¢ Alkaline phosphatase  
‚Ä¢ Total protein  
‚Ä¢ Potassium  
‚Ä¢ Sodium  
‚Ä¢ Calcium  
‚Ä¢ Glucose (fasting) (e) 
‚Ä¢ GGT  
Routine urinalysis  ‚Ä¢ Specific gravity, appearance, color  
‚Ä¢ pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase  
‚Ä¢ Microscopic examination (if blood or protein is abnormal)  
Other screening tests  ‚Ä¢ FSH if menopause is suspected(b)  
‚Ä¢ Urine drug screen including amphetamines (including methamphetamine), barbiturates, benzodiazepines, cannabinoids, cocaine, opiates, methadone, and phencyclidine  
‚Ä¢ Serum hCG pregnancy test(c) at Screening Visit 1  
‚Ä¢ Urine hCG pregnancy test(c) at Run- In Period Visit 2, randomization Visit 3, and final 
visit for On -Demand Treatment Period Visit 5 7 
‚Ä¢ Serology (HIV antibody, HBsAg, and HCV antibody; hepatitis C, viral load RNA(d) [qualitative])  
‚Ä¢ Serum gastrin (fasting  12 hours ) and serum pepsinogen I and II levels will also be 
evaluated as safety/PD biomarkers at Day - 1 of Run- In Period ; Week 4 of Run- In 
Period; Week 6 of On- Demand Treatment Period; and safety follow -up visit. Day -1 
baseline gastrin levels will not be blinded.  Gastrin at the Week 4 Run -In, Week 6 
On-Demand treatment, and  Safety Follow -up visits  and all pepsinogen I and II 
results will be blinded and will not  be reported to investigative sites or other blinded 
personnel until after  the study blind is broken.  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 109 Laboratory 
Assessments  Parameters  
Abbreviations: ALT,  alanine aminotransferase; AST,  aspartate aminotransferase; FSH, follicle -stimulating 
hormone; GGT, gamma -glutamyl transferase; HBsAg, hepatitis B surface antigen; hCG, human 
chorionic gonadotropin; HCV , hepatitis C virus; H I V,  human immunodeficiency virus; MCH,  mean 
corpuscular hemoglobin; MCV ,  mean corpuscular volume; PD, pharmacodynamics; RBC, red blood cell; 
SGOT,  serum glutamic -oxaloacetic transaminase; SGPT, serum glutamic- pyruvic transaminase; WBC, 
white blood cell.  
(a)  See Section  13.3 for the appropriate guidance on reporting of abnormal liver function t ests. For liver 
funct
ion test monitoring, see Section 13.3.1.  For temporary and permanent discontinuation of study 
drugs  due to abnormal liver function tests, see Section 13.3.2 a nd Section 13.3.3,  respectively.  
(b)  Follicle stimulating hormone will be conducted at the investigator‚Äôs discretion to determine the 
postmenopausal status of womenRequired only for confirmation of postmenopausal females as 
defined in Section 13.2 (Appendix 2).  Women  whose duration of (consecutive) amenorrhea is 
borderline or open  to doubt and where the investigator believes the subject to be menopausal by history 
should have confirmatory FSH drawn. 
(c)  As needed for women of childbearing potential. During the Run- In Period and On- Demand Treatment 
Period, serum pregnancy test will be performed if the urine pregnancy test is positive.  
(d)  Reflex - if hepatitis C positive.  
(e) 8 hours fasting at Screening Visit 1 . 
 
Vital Signs ( Section  6.3.5)  
Vital signs will include body temperature (oral, temporal, or tympanic measurement), sitting 
blood pressure (resting more than 5 minutes), and heart rate (beats per minute). When vital signs 
are scheduled at the same time as blood collections, the blood collections will take priority.   
Electrocardiograms ( Section  6.3.6)  
A standard 12- lead ECG will be recorded. The investigator (or a qualified observer at the 
investigational site) will interpret the ECG using one of the following categories: within normal limits, abnormal but not clinically significant, or abnormal and clinically significant. The following parameters will be recorded on the eCRF from the subject‚Äôs ECG trace: heart rate, PR 
interval, RR interval,  QT interval, QTcF (derived)  and QRS interval. A copy of the ECG trace 
should be kept with the subject‚Äôs notes. For ECG results printed on thermal paper, nonthermal 
paper copies should be made to avoid degradation of trace over time. 
Sample Size Calculations ( Section  7.1) 
Based on these assumptions, a sample size of 200 heartburn episodes per treatment group (or 50 subjects with at least 4 heartburn episodes per treatment group) provides at least 80% statistical power at the significance level of 0.05. During the study if less than 200 subjects are 
proje cted to enroll into the On -Demand Treatment Period, additional subjects may be 
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 110 enrolled into the Run- In Period to ensure that a sufficient number of subjects enroll into 
the On -Demand Treatment Period.  
Assuming 4060% of subjects at the end of the Run- In Pe riod do not meet the eligibility criteria 
for the On -Demand Treatment Period, a total of 334 approximately 500 subjects will be 
enrolled into the Run-In Period to achieve 200 subjects for the On- Demand Treatment Period.  
Intent -to-Treat Set (Section  7.2.3)  
The ITT On -Demand set includes all subjects in the Safety On Demand Run-In set who were 
randomized and completed at least one heartburn episode diary during the On- Demand 
Treatment Period.  
Description of Subgroups ( Section  7.3) 
‚Ä¢ mean heartburn severity during the Run InScreening  Period (mild, moderate, severe, 
very severe)  
Phathom Pharmaceuticals, Inc. vonoprazan  
Protocol: NERD -201 Version 2.0, Amendment 1  16 July 2021  
Page 113 (a)  Visit window is Day - 36 to Day - 2 for assessment of clinical laboratory assessments, ECG, and endoscopy in the Screening Period. Any endoscopic confirmation 
performed in a routine clinical setting within 7 days before signing the informed consent is acceptable to use for the purpos e of fulfilling the screening requirement.  
(b)  At an unscheduled visit, the following procedures are to be completed with additional procedures at the investigator‚Äôs discretion: a brief physical examination, vital 
sign measurements, concomitant medication assessment, AE assessment, and clinical laboratory tests. If the visit results in p remature termination, then all 
procedures outlined for the  Final  final  visit should be performed.  
(c)  The date of first dosing day is defined as Day 1 in both Run- In Period and On -Demand Treatment Period. The date of randomization is defined as Day - 1 of On -
Demand Treatment Period.  
(d)  Subjects shoul d continue to meet inclusion criteria ( Section 4.1.1.1) and exclusion criteria ( Section 4.1.1.2), except Inclusion Criteria Criterion  4. 
(e) Full physical examination is performed at ScreeningPeriod ; a brief physical examination is performed at all other visits.  
(f) Required only for confirmation of postmenopausal females as described in Section 13.2 (Appendix 2) . Women whose duration of (consecutive) amenorrhea is 
borderline or open to doubt and where the investigator believes the subject to be menopausal by history should have confirmatory FSH drawn. 
(g)  See Section 6.3.3  and Table 6 -4 for all required laboratory assessments.  
(h)  Gastrin Week 4 Run- In, Week 6 On- Demand treatment and Safety follow -up visits and pepsinogen I and II results will be blinded and will not be reported to 
investigative sites or other blinded personnel until the study blind is broken.  
(i)  Only female subjects with childbearing potential. Serum hCG at screening and urine hCG at all subsequent visits.  
(j)  The screening endoscopy can be performed any time during that period; however, it should be performed after the subject has f ulfilled all other admission criteria. 
Any endoscopic confirmation performed in a routine clinical setting within 7 days before signing the informed consent is acceptable to use for the purpose of 
fulfilling the screening requirement.  
(k)  Subjects should be instructed to complete the electronic diary every morning upon waking (for nighttime symptoms) and every evening before bedtime (for daytime symptoms) on each day of the Screening, Run- In and Follow -up Period. During the On -Demand Treatment Period, subjects will be instructed to complete the 
electronic diary to document heartburn episodes and study drug administration. Rescue antacid use should be reported during all periods.  
(l)  Subjects are to start dose administration from Day 1.  
(m)  Rescue antacid will be dispensed as needed after the Screening Period.  
(n)  Sites will document dispensing rescue antacid. Subjects do not need to return unused rescue antacid.  
(o) Day - 1 baseline gastrin levels will not be blinded.  
(p) Run- In failure procedures.  
 
 